Systems Biology Approaches to Evaluate Disease Modularity by Reyes Palomares, Armando Adolfo

AUTOR: Armando Reyes Palomares
EDITA: Publicaciones y Divulgación Científica. Universidad de Málaga
Esta obra está sujeta a una licencia Creative Commons:
Reconocimiento - No comercial - SinObraDerivada (cc-by-nc-nd):
Http://creativecommons.org/licences/by-nc-nd/3.0/es
Cualquier parte de esta obra se puede reproducir sin autorización 
pero con el reconocimiento y atribución de los autores.
No se puede hacer uso comercial de la obra y no se puede alterar, transformar o hacer 
obras derivadas.
Esta Tesis Doctoral está depositada en el Repositorio Institucional de la Universidad de 
Málaga (RIUMA):  riuma.uma.es
 Systems Biology Approaches 
to Evaluate 
Disease Modularity 
 
 
 
 
Armando Reyes Palomares 
 
TESIS DOCTORAL 
 
 
 
Departamento de Biología Molecular y Bioquímica 
Facultad de Ciencias 
 
Málaga, 2014
 Systems Biology Approaches 
to Evaluate 
Disease Modularity 
 
Memoria presentada para optar al grado de 
 Doctor por la Universidad de Málaga 
 
Armando Reyes Palomares 
 
 
 
DIRECTORES 
 
 
 
 
Miguel Ángel Medina Torres 
Catedrático de Bioquímica y 
Biología Molecular de la 
Universidad de Málaga 
Francisca Sánchez Jiménez 
Catedrática de Bioquímica y 
Biología Molecular de la 
Universidad de Málaga 
 
  
 
 
 
Miguel Ángel Medina Torres, Catedrático de Bioquímica y Biología 
Molecular de la Universidad Málaga, Francisca Mª Sánchez Jiménez, 
Catedrática de Bioquímica y Biología Molecular de la Universidad Málaga 
 
 
CERTIFICAN 
 
Que D. Armando Reyes Palomares, Licenciado en Biología por la 
Universidad de Málaga, ha realizado bajo nuestra dirección conjunta en el 
Departamento de Biología Molecular y Bioquímica de la Universidad de 
Málaga el trabajo de investigación correspondiente a su Tesis Doctoral que 
lleva por título “Systems Biology Approaches to Evaluate Disease 
Modularity”. 
 
Este trabajo reúne, a nuestro juicio, contenido científico suficiente y las 
condiciones necesarias para ser presentado y defendido ante el tribunal 
correspondiente para optar al grado de Doctor. 
 
Málaga, Marzo de 2014 
 
 
 
 
 
 
 
 
 
Miguel Ángel Medina Torres  
 
 
 
 
 
 
 
 
Francisca Sánchez Jiménez 
 
 
! 
 
 
 
 
 
 
 
 
 
 
  
 
         
 
  
   
 
 
     
 
 
 
The research in this Doctoral Thesis titled 'Systems Biology Approaches to 
Evaluate Disease modularity' was carried out at the group PAIDI BIO-267 of 
the Department of Molecular Biology and Biochemistry of University of 
Malaga. The author and supervisors also belongs to the unit 741 of Centre for 
Biomedical Network Research on Rare Diseases (CIBERER). 
 
This research has been funded by the CIBERER and Grants SAF2011-26528 
(MEC, Spain), CVI-06585 and CTS-1507 (Junta de Andalucia and FEDER), 
and AMER Consorptium (FEDER-Innterconecta, CDTI, Spain). This work is 
one of the activities for the Bioinformatic Platform for Rare Diseases (BIER) of 
CIBERER, which is an initiative of "Instituto de Salud Caros III". 
 
The author of this Thesis has been recipient of a Training University 
Lecturers (Competitive FPU Grant from Spanish Ministry of Education). 
! 
PUBLICATIONS 
List of publications included in this Thesis: 
 
A combined model of hepatic polyamine and sulfur amino acid metabolism 
to analyze S-adenosyl methionine availability 
Reyes-Palomares A, Montañez R, Sánchez-Jiménez F, Medina MA.  
Amino Acids. 2012 Feb;42(2-3):597-610. 
doi:10.1007/s00726-011-1035-7. 
 
Systems biology metabolic modeling assistant: an ontology-based tool for 
the integration of metabolic data in kinetic modeling 
Reyes-Palomares A*, Montañez R*, Real-Chicharro A, Chniber O, Kerzazi A, Navas-
Delgado I, Medina MA, Aldana-Montes JF, Sánchez-Jiménez F. 
Bioinformatics. 2009 Mar 15;25(6):834-5. doi:10.1093/bioinformatics/btp061. 
 
Global analysis of the human pathophenotypic similarity gene network 
merges disease module components 
Reyes-Palomares A, Rodríguez-López R, Ranea JA, Sánchez Jiménez F, Medina MA.  
PLoS One. 2013;8(2):e56653.  
doi: 10.1371/journal.pone.0056653. 
 
PhenUMA: A Tool for Integrating the Biomedical Relationships among 
Genes and Diseases 
Rodríguez-López R*, Reyes-Palomares A*, Sánchez-Jiménez F, and Medina MA.  
(Submitted to BMC Genomics) 
 
Network Medicine Approaches for Systematic Identification of Phenotype 
and Structural Variants Associations 
Reyes-Palomares A. et al. 
(Manuscript in preparation) 
 
∗ These authors have contributed equally. 
 
! 
OTHER PUBLICATIONS 
List of publications not included in this Thesis: 
 
 
Regulatory cross-talk of mouse liver polyamine and methionine metabolic 
pathways: a systemic approach to its physiopathological consequences.  
Correa-Fiz F, Reyes-Palomares A, Fajardo I, Melgarejo E, Gutiérrez A, García-Ranea 
JA, Medina MA, Sánchez-Jiménez F.  
Amino Acids. 2012 Feb;42(2-3):577-95. 
doi: 10.1007/s00726-011-1044-6. 
 
What is known on angiogenesis-related rare diseases? A systematic review 
of literature.  
Rodríguez-Caso L, Reyes-Palomares A, Sánchez-Jiménez F, Quesada AR, Medina 
MÁ.  
J Cell Mol Med. 2012 Dec;16(12):2872-93.  
doi: 10.1111/j.1582-4934.2012.01616.x. Review. 
 
Histamine: an undercover agent in multiple rare diseases? 
Pino-Ángeles A, Reyes-Palomares A, Melgarejo E, Sánchez-Jiménez F.  
J Cell Mol Med. 2012 Sep;16(9):1947-60. 
doi: 10.1111/j.1582-4934.2012.01566.x. Review. 
 
First steps in computational systems biology: A practical session in 
metabolic modeling and simulation. 
Reyes-Palomares A, Sánchez-Jiménez F, Medina MÁ. 
Biochem Mol Biol Educ. 2009 May;37(3):178-81. 
doi: 10.1002/bmb.20281. 
  
! 
AGRADECIMIENTOS 
Estimados compañeros, son muchos años con vosotros y la lista de agradecimientos es extensa 
afortunadamente. Antes de escribir estas palabras no he podido evitar pensar en perspectiva de 
lo que representa esa lista. Así que mentalmente la he esbozado como una red (deformación 
profesional), en la que los nodos sois vosotros y las relaciones pues se establecen en función de lo 
compartido como esfuerzos, afinidades y vivencias tanto personales como profesionales; o 
también los hay por pura coincidencia, pero que también cuentan porque el roce hace el cariño.  
 
 A simple vista, en esa "red" de relaciones humanas y profesionales destacan dos enormes 
"hubs". Miguel Ángel y Kika, muchas gracias por permitirme disfrutar del uso libre de mi 
propio razonamiento. Las pruebas las tenéis, podría haber hecho esto algo antes, pero no ha 
sido así porque estaba muy a gusto con vosotros. Me siento muy afortunado de que seáis mis 
directores, compañeros y amigos. 
 
 Miguel Ángel, tu me fichaste. Mis ambiciones estaban adormecidas y carecía de un reto 
claro ante un sistema educativo muy limitado para las mentes inquietas y creativas. Sin 
embargo, con tus asignaturas me presentaste un nuevo horizonte, una forma alternativa de 
expresar mis conocimientos y de entrenar mis habilidades. Desde que me senté en tu despacho 
para plantear los primeros proyectos, me lo dejaste tajantemente claro, "ten en cuenta que para 
este trabajo tienes que ser autodidacta". A priori no entendía muy bien eso de ser autónomo en 
un colectivo de investigación; pero no tuvo que pasar mucho tiempo para darme cuenta del reto 
que me planteabas, algo así como: "sapere aude chaval" (eso de "chaval", obviamente, es cosecha 
propia). Muchas gracias por enseñarme unas pautas tan esenciales, dejar que me desahogue con 
mis tensiones y ayudarme a relativizarlas, así como darme tu opinión, siempre cuidadosamente 
aséptica para no influenciarme, en la toma de decisiones muy importantes para mi. 
 
 Kika, que te voy a decir que no sepas todo lo que te debo, como tu dices conectamos 
bien y no nos hacen falta muchas palabras para entendernos. Pero, muchas gracias porque sin 
acabar la carrera apostate por mí para formar parte de un nuevo proyecto para el grupo al que 
nos presentamos como una unidad completa de biocomputación. En esa época, no era muy 
consciente de como funcionaban estas cosas, pero ahora con más perspectiva pienso con 
absoluta franqueza que fuiste valiente. Todo maestro tiene su librillo pero tu debes de tener 
unos cuantos porque nadie ponía en duda la seguridad que emanaba ese sexteto de becarios (el 
largo, almu, raúl, ian, ale y un servidor). Puede que fuéramos –y seamos– algo frikis pero con la 
moral de legionarios. Muchas gracias por esa inyección de moral, ese buen rollo, tus empujones 
para tomar iniciativas y ser tan ecuánime al tomar decisiones difíciles dentro del colectivo. He 
sido y soy testigo directo de tu perseverancia y dedicación a la profesión. Así como lo has sido en 
los asuntos más cercanos a mi también lo has sido con él/la/los que se sienta/n a mi lado 
(between o among lo mismo da :) ). 
! 
 Muchas gracias al "Computational Biology and Data Mining Research Group" del 
"Max Delbrück Center for Molecular Medicine" por acogerme durante 3 meses de estancia 
predoctoral. Fue una experiencia fabulosa y me sentí como en casa, me encantó el grupo y 
conocí a muy buenos amigos: Miguel, Nancy, Enrique, Jean-Fred, David, Arvind, Martin y 
Merie. 
 
 En cuanto a los Seniors del grupo. Juan Antonio, son muchos años mesa con mesa y 
compartiendo almuerzos. Gracias por tu valiosos consejos. Para mi es un placer tenerte como 
amigo y compañero, y opino que gente como tu, con perspectiva y gran dinamismo, es 
fundamental para agilizar la universidad más aún si cabe en esta época. Nos conocemos 
bastante bien, tu sabes muchos de mis secretos y yo sé que no te vas sin comprobar tu 
archivador ; ) . José Luis e Ignacio, aunque no lo sepáis en los seminarios aprendí mucho de 
vuestros comentarios, preguntas y discusiones con Kika o MAM sobre los experimentos de los 
compañeros con bata, gracias. Ana, directora, gracias por tu amabilidad facilitando esas 
variopintas consultas o gestiones. 
 
 Los demás componentes de esta red modular. El lado oscuro, en el que he encontrado 
buenos compañeros y amigos, además de compartir una gran cantidad de horas de trabajo. 
Alejandro y Rocío habéis sido mis dos tendones de Aquiles. Si alguien me dice bioinformático 
tiene que saber que la parte informática es fundamentalmente gracias a vosotros. He tenido la 
suerte de conoceros y entenderme perfectamente con ambos, tanto en lo profesional como en lo 
personal. Rocío, eres una gran "aprendiz". En un período corto de tiempo hemos entablado una 
buena amistad, obtenido buenos resultados, organizado eventos científicos y nos han agraciado 
con un premio honorífico. ¡¡no se puede pedir más!! ;) Rubio se te echa de menos, tu 
personalidad era la chispa del mejor de los ambientes... si, si, ambientes de los que a ti te gustan. 
Nunca olvidaré ese viaje a Ámsterdam dos chavalines con todo el equipo de desarrolladores de 
Cytoscape... un momento genuino!! Raúl, gracias compañero por compartir esas largas jornadas 
de trabajo y combinarlas con buenas aventuras (Tenerife, Barcelona, Valencia, etc.). Eres un 
trabajador nato y un artista pero de los de verdad. Aure y Almu, dos inseparables que en menos 
de un año habéis volado los dos. Durante tres añitos fuimos el equipo ciberero todo un 
escuadrón. Muchas gracias a ambos porque vuestra efectiva organización siempre me ha sido de 
gran ayuda y referencia. Ian, el matemático descifrador,  horas y horas de matlab, con mucha 
personalidad y excelente persona. Jim, my British mate. Thanks for sharing scientific discussion 
with me, but also talk to you about whatever topic society, sports, perspectives... I was thinking, 
it should be fine to resume beer sessions. Bea y Aníbal, la "nueva" remesa del lado oscuro, 
proyectos de ingenieros bioinformáticos, ánimos que ya mismo os vendrá la mejor parte, y 
sabéis que podéis contar conmigo. Muchas gracias también al resto del grupo; un pedazo de 
"wet lab" (pasado y presente, os podría decir mucho a todos y cada uno de vosotros pero sois 
tantos): Hicham (queda pendiente ese cafelito de moda), Betty :), Gianni, Melissa (me pusiste las 
pilas con la Tesis, gracias), Flor, María Victoria, Javi, Luiso (muchas gracias por tus reflexivas 
visitas) y Carmen, Esther, Casimiro, Auxi, Carlos^2, Joaquín.  
 
Por último, quiero agradecérselo a mis familiares y amigos, a los que les debo la vida así como el 
día a día. 
 
 En primer lugar, a mi clon genético mi hermano. Gracias por todo Arturo, vivo con la 
tranquilidad y la confianza, estando más lejos o más cerca, de tenerte siempre a mi lado. Eres 
una gran persona, estoy muy orgulloso de ti. Este trabajo –en parte– también es tuyo porque a 
saber en que momento embrionario los dos dejamos de ser uno. 
 
 A mi madre, Sissi la emperatriz de Málaga. Gracias por velar por nuestra felicidad 
incondicionalmente, nos cuidaste dando el más sólido apoyo, y nos concediste la libertad y la 
responsabilidad de ser nosotros mismos y con nuestras circunstancias. Siempre nos tendrás a los 
dos aunque nunca podremos recompensarte por todo lo que nos has dado. 
! 
 A mi padre,  siempre he dicho que uno puede ser feliz descubriendo y trabajando de lo 
que más conoce. Tu nos enseñaste a deducir y a razonar, para reconocer con criterio la 
importancia de las cosas y la relatividad de las apariencias. Te agradezco tus lecciones y tu 
empeño en que las aprendiéramos, siempre nos ayudaste para que aprendiéramos a motivarnos. 
 
 A Antonia y Lázaro, mi mezcla peligrosa ;) que nos criaron y aguantaron toda nuestra 
infancia y adolescencia, con la paciencia y la sabiduría de los ancianos. Nunca olvidaré lo que 
representáis para nosotros. A Manolo, muchas gracias por confiar en nosotros y querernos 
como a sobrinos, siempre ayudas a ver lo sencilla que pueden ser las cosas, la vida. José desde 
pequeño seguimos juntos primos y mejores amigos, a Lulú, a mi abuelo Adolfo y a la Chica, a 
Lourdes y Almudena, demás familia y amigos, muchas gracias por compartir vuestras vidas 
conmigo y apoyarme de corazón. 
 
 Por último, mi compañera la dueña de mis pasiones, María, que has sido testigo en 
primera línea de este trabajo. Gracias por aguantarme, mimarme y amarme como desde el 
primer día. 
 
Gracias 
 
 
 
 
 
 
!CONTENTS 
CONTENTS'.............................................................................................................................................'1!
PREÁMBULO'.........................................................................................................................................'3!
ABSTRACT'.............................................................................................................................................'7!
CHAPTER'1'............................................................................................................................................'9!
INTRODUCTION'...................................................................................................................................'9!SYSTEMS!BIOLOGY!................................................................................................................................................!10!
Modular(organization(of(biological(systems(......................................................................................(13!EMERGENCE!OF!PHENOTYPIC!VARIABILITY!.....................................................................................................!17!
The(organization(of(phenotypes(in(the(genotype(space(................................................................(17!
Universal(or(Restricted(Pleiotropy?(The(debate(................................................................................(19!THE!MODULAR!NATURE!OF!GENETIC!DISEASES!..............................................................................................!21!INTEGRATIVE!SYSTEMS!BIOLOGY!APPROACHES!..............................................................................................!25!
Data(mining(and(alignment(.......................................................................................................................(25!
Probabilistic(and(mathematical(modelling(........................................................................................(26!
NetworkIbased(analysis(...............................................................................................................................(27!STATE!OF!THE!ART.!FROM!OMICS!TO!GENOME!MEDICINE.!...........................................................................!28!
CHAPTER'2'.........................................................................................................................................'31!
HYPOTHESIS'&'OBJECTIVES'.........................................................................................................'31!
CHAPTER'3'.........................................................................................................................................'33!
RESULTS.'THESIS'PUBLICATIONS.'..............................................................................................'33!
CHAPTER'4'.........................................................................................................................................'53!
DISCUSSION'......................................................................................................................................'ͳ͸3!
Functional(modularity(in(biological(systems(...................................................................................ͷͼ3!
Evaluating(disease(modularity(..............................................................................................................(ͷͼ4!
Standardization(efforts(.............................................................................................................................ͷͼ5!
Network(medicine(approaches(using(patient(data(......................................................................ͷͼ7!
CHAPTER'5'.......................................................................................................................................'ͳ͸9!
CONCLUSIONS'..................................................................................................................................'ͳ͸9!
CHAPTER'5'.......................................................................................................................................'ͳ͹1!
CONCLUSIONES'...............................................................................................................................'ͳ͹1!
REFERENCES'....................................................................................................................................'ͳ͹3!
GLOBAL'SUMMARY'OF'RESULTS'...............................................................................................'ͳͺ1!METABOLIC!MODELLING!.................................................................................................................................!ͳͺ1!NETWORK!MEDICINE!APPROACHES!..............................................................................................................!ͳͺ6!
RESUMEN'GLOBAL'DE'LOS'RESULTADOS'...............................................................................'ͳͻ1!MODELADO!METABÓLICO.!...............................................................................................................................!ͳͻ1!APROXIMACIONES!BASADAS!EN!REDES!DE!LA!MEDICINA.!..........................................................................!ͳͻ6!
Page 1 of 210
! 
PREÁMBULO 
En el curso 2006-2007, sin haber acabado la carrera fue cuando me inicié en el 
mundo de la investigación. Pero mi aventura realmente comenzó un curso antes, 
estudiando bioquímica metabólica que impartía mi director de tesis, Miguel 
Ángel Medina Torres. En aquel curso académico descubrí un mundo de 
posibilidades y distinto a lo que habitualmente cualquier alumno aprende en las 
aulas. A este mundo, en concreto, lo suelo llamar como el "mercado del 
conocimiento" en biología molecular y bioquímica, como explicaré más adelante. 
Pero permita que continúe explicando mi experiencia didáctica. Miguel Ángel, 
nos propuso como única tarea obligatoria que los propios alumnos diseñáramos 
una práctica lo razonablemente afín a los contenidos de la asignatura. A pesar de 
que algunos no entienden la finalidad de esta tarea, todo el que la trabaja suele 
acabar convencido de que es una experiencia enriquecedora. La realidad 
objetiva de esta tarea es que si quieres aprender algo, lo que tienes que demostrar 
es que eres capaz de explicarlo. Él exige esta garantía para que el alumno estudie 
con bastante profundidad un tema como para llegar casi a dominarlo. 
 
 De alguna manera, para darle alguna pista de mi argumento, pretendo 
recalcar que cualquier conocimiento adquirido debe ser formalizado –o 
estandarizado– para que otros lo puedan entender. Por aquel entonces, ya 
disponía de ciertas habilidades para la informática pero carecía de conocimientos 
en programación y computación. Después de explorar y reflexionar, le propuse a 
Miguel Ángel diseñar una práctica con la que cualquier alumno pudiera hacer un 
modelo matemático de una ruta metabólica como la glucolisis. Tras su visto,  
como alumno me planteé ¿qué alumno de 3º de biología puede aprender en una 
sola práctica todos esos conocimientos en matemáticas y en programación? Fue 
entonces, en junio de 2005, después de días documentándome e investigando 
cuando descubrí las puertas del "mercado de conocimiento". Y digo las puertas 
porque esto solo es el principio del viaje hasta acabar de escribir esta tesis. En 
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!primer lugar, encontré mucho software de programas para diseñar y simular 
rutas metabólicas (CellDesigner®, CoPaSi o GePaSi, Systems Biology 
WorkBench, etc.), diversas bases de datos de información metabólica y 
enzimática (BRENDA, SABIO-RK, EMP, KEGG) y repositorios con modelos 
metabólicos completos y funcionales (JWS-Online y BioModels). Una de los 
mayores ventajas de este mercado es que todo es open-source, y cualquiera podía 
–y aún puede– servirse a su gusto con fines académicos.  
 
 Había topado con la cuna de la biología de sistemas, una corriente de 
planteamientos innovadores, atractivos y acordes a las necesidades de lo que 
buscaba para mi tarea de bioquímica metabólica. Toda una casta de científicos 
con un perfil mayoritariamente tecnológico, tales como Hiroaki Kitano del 
"Systems Biology Institute" o John C. Doyle y Michael Hucka del "California 
Institute of Technology",  fundaron una plataforma que se denominó "SBML 
Systems Biology Markup Language" (SBML, http://www.sbml.org/). Esta 
plataforma, se  inició en 2001 y fue evolucionando progresivamente hasta 
convertir al SBML en el formato estándar para transferir y almacenar la 
información mínima que se requiere para diseñar un modelo biológico, 
principalmente orientado a la modelización de reacciones bioquímicas. Este 
formato es compatible con múltiples programas que utilizan la misma 
información pero con propósitos muy distintos, un mercado que presenta 
múltiples ofertas y que cada uno puede servirse libremente. Por ejemplo, algunos 
utilizan ficheros SBML para visualizar la información utilizando diversas 
notaciones gráficas, como por ejemplo la "Systems Biology Graphical Notation" 
(SBGN, http://www.sbgn.org/). Otros permiten hacer un estudio estructural del 
conjunto de reacciones descritas en los modelos (ficheros SBML) a partir de sus 
estequiometrias, como por ejemplo el análisis de las sub-redes  mínimas que 
permiten mantener un estado estacionario ("elementary flux modes"). Sin 
embargo, para mi práctica, utilicé programas para diseñar y analizar modelos 
metabólicos a partir de la información cinética enzimática conocida para cada 
reacción. Escogí este tipo de programas porque permiten estudiar a la vez las 
propiedades dinámicas y estructurales de un conjunto de reacciones bioquímicas 
en cuestión. Estos programas solo requieren introducir de forma ordenada las 
ecuaciones y los parámetros cinéticos de cada reacción para hacer las 
simulaciones y estudiar como cambian las concentraciones de los metabolitos y 
los flujos metabólicos a lo largo del tiempo.  
La trayectoria que he vivido en primera persona del proyecto SBML, me permite 
afirmar que formalizó unos estándares básicos –y prácticos– para asentar los 
fundamentos de la modelización de la biología de sistemas actual, tras 
consolidarse como disciplina académica hace algo más de una década. Gracias al 
software disponible, a la variedad de algoritmos desarrollados, a los repositorios 
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!de modelos online y a las facilidades que ha aportado este proyecto al resto de 
miembros de la comunidad científica, es posible una lección práctica sobre la 
modelización de la glucolisis en una sesión de 3 horas en el aula de informática.  
Utilizando todos estos recursos fue como me inicié en la investigación, diseñando 
una actividad con fines docentes que todavía impartimos Miguel Ángel y yo 
desde entonces. 
 
 En el año 2007, me incorporé como asistente de investigación a la unidad 
741 del Centro de Investigaciones Biomédicas en Red de Enfermedades Raras 
(CIBERER) dirigida por Francisca Sánchez Jiménez, mi co-directora. CIBERER 
era un proyecto de ámbito nacional y gracias al cual siguen contratados algunos 
miembros de nuestro grupo. En 2010, el Ministerio de Educación y Ciencia me 
concedió una beca del Programa Nacional de Formación de Profesorado 
Universitario que he disfrutado hasta la fecha propuesta para la defensa de esta 
Tesis Doctoral. 
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ABSTRACT 
Biological systems are in a constant process of innovation as an essential 
precondition to evolve. For this reason, the emergence of phenotypic variation is 
an inherent property of complex adaptive systems. Even though living systems 
acquire robustness to internal and external disturbances during the evolutionary 
process, pathological conditions entail impairments to their functionality. This is 
the rationale for studying biomedical issues according to the organizational 
properties of biological systems, with the aim of understanding the mechanisms of 
diseases.  
 I first discuss the theoretical background that is suitable for the research 
included in this Thesis, such as my own interpretation of systems biology, the 
current theories about the origin of the biological modularity and some 
evolutionary considerations that concern in the genotype-phenotype 
relationships. In this section, I also argue the use and the development of 
integrative systems biology methods that should be addressed to evaluate disease 
modules: computational models (i.e. mathematical and network-based models) 
and other standardized efforts (ontologies and different databases with biological 
and biomedical data). Then, I enunciate the hypothesis and declare the objectives 
that motivated this research: i) mathematical modelling based on kinetic law 
formalism for studying the functional modularity of the metabolism; ii) the 
development of a workflow to integrate metabolic and kinetic data from different 
databases for metabolic modelling; iii) the evaluation of the functional coherence 
in phenotypic relationships between disease-causing genes by using network-
based analysis; iv) the development of an integrative framework of biomedical 
information; v) the use of network medicine approaches to study the phenotypic 
and genotypic relationships in a heterogeneous group of patients with genetic 
syndromes. Finally, the results derived from the research carried out in this 
Thesis are included in the form of already published articles and manuscripts 
(either submitted or in preparation). 
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CHAPTER 1 
 INTRODUCTION 
The challenge of modern biology is to understand the structural and functional 
properties of complex adaptive systems. In the case of cellular networks, the 
notion of module is the abstraction of interconnected biomolecules from whole 
molecular interactions in cells1,2. I argue that this abstraction can be supported by 
topological and functional criteria, but to understand how biological structures 
integrate functionality is necessary to consider their dynamical singularities. This 
is the rationale behind the approaches of systems biology3–5. In fact, only on the 
basis of the fundamental organization of biological systems is possible to evaluate 
how modularity –or any other systemic property– pervades living things. Systems 
biology approaches are aimed for a deeper understanding of certain biomedical 
issues6,7. Many integration efforts are made in this direction. Here, I focus only 
on diseases with a genetic origin, where their molecular bases are known or they 
show a pattern of inheritance. This means that at least one genotype predisposes 
to suffer or express any or several of the clinical features classically recognised in 
these medical conditions. This points to another issue concerning how these 
pathological conditions depend on the modular architecture of the underlying 
biology. 
 
 In this section, the theoretical background suitable for the research studies 
included in this Thesis is introduced. First, I describe my perception on the 
current systemic view of biology and the current theories about the origin of the 
modular organization in biology. I continue with an overview of the evolutionary 
processes that involve the emergence of phenotypes and how they can be related 
to the modular nature of genetic diseases. Finally, I summarize the state of the art 
of established and emerging ‘omic technologies with biomedical applications and 
some aspects of the integrative systems biology approach used in this Thesis.  
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CHAPTER 2 
HYPOTHESIS & OBJECTIVES 
Living systems are in a constant process of innovation as an essential 
precondition to evolve. This innovation process is not intended to provide the 
most appropriate features in the short-term, but simply to create new biological 
features. Subsequent evolutionary processes are the responsible for shaping 
structural and functional properties of biological systems over long periods of 
time. Under these circumstances, it should be assumed that the manifestation of 
pathological process is inherent in our biology. Despite biological systems acquire 
robustness to internal and external changes such as genetic variations and 
environmental fluctuations respectively29; the disease state entails an impairment 
of functionality (loss of phenotypic robustness). This is the rationale for studying 
human diseases according to the organizational properties of biological adaptive 
systems, with the aim of understanding how they affect their fitness. The 
incidence of genetic diseases in the population is the consequence of certain 
biological constraints and susceptible to be studied by a systemic view. It could be 
considered as the main hypothesis underlying this thesis. Nonetheless, there are 
two premises that actually constitute the specific hypotheses of this Thesis.  
 
 First hypothesis: The computational approaches are required to study the modular 
organization of biological systems. In particular, I will focus on biochemical reaction 
systems that conform metabolic modules related to the S-adenosylmethionine. 
 
 Second hypothesis: The phenotypic coherence between disease-causing genes 
depends on their functional context. For this reason, the integration of molecular 
interactions underlying the genotype-phenotype relationship is helpful to 
elucidate the modularity of genetic diseases. 
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! This Thesis emphasizes the use and the development of integrative systems 
biology approaches, such as computational models and standard methods, which 
should be addressed to outline the modularity of diseases. Thus, to study and test 
these hypotheses we defined the following objectives: 
 
Objective 1. The use of mathematical modelling based on kinetic law formalism 
to study the functional properties of the modularity in the metabolism. In 
particular, I will use different metabolic models to evaluate how biochemical 
reactions determine the availability of S-adenosylmethione, one of the main 
precursors of polyamines and an essential methyl donor in cells. 
 
Objective 2. The development of a workflow that integrates metabolic and 
kinetic data from different databases and helpful to design or extend metabolic 
models. For this objective, the workflow should comply with the current 
proposals to standardize models of biochemical reactions, concretely those that 
have been agreed in the various consortia and international groups of systems 
biology, such as the use of ontologies and formats agreed (i.e. SBML). 
 
Objective 3. The evaluation of functional coherence in phenotypic relationships 
between disease-causing genes by using network-based analysis. The phenotypic 
relationships will be established by calculating semantic similarity between genes 
through the use of an ontology of human abnormalities. 
 
Objective 4. The development of a tool to integrate phenotypic and functional 
relationships between genes, diseases and phenotypes. This tool will be freely 
available online and will be built according to the discussions and conclusions 
derived from the results obtained for the fulfilment of the previous aim. 
 
Objective 5. The use of network medicine approaches to study the phenotypic 
and genotypic relationships in a heterogeneous group of patients with genetic 
syndromes. 
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3.1. A combined model of hepatic polyamine and sulfur amino 
acid metabolism to analyze S-adenosyl methionine availability 
 
 
3.2. Systems biology metabolic modeling assistant: an ontology-
based tool for the integration of metabolic data in kinetic 
modeling 
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gene network merges disease module components 
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Global Analysis of the Human Pathophenotypic
Similarity Gene Network Merges Disease Module
Components
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Abstract
The molecular complexity of genetic diseases requires novel approaches to break it down into coherent biological modules.
For this purpose, many disease network models have been created and analyzed. We highlight two of them, ‘‘the human
diseases networks’’ (HDN) and ‘‘the orphan disease networks’’ (ODN). However, in these models, each single node
represents one disease or an ambiguous group of diseases. In these cases, the notion of diseases as unique entities reduces
the usefulness of network-based methods. We hypothesize that using the clinical features (pathophenotypes) to define
pathophenotypic connections between disease-causing genes improve our understanding of the molecular events
originated by genetic disturbances. For this, we have built a pathophenotypic similarity gene network (PSGN) and
compared it with the unipartite projections (based on gene-to-gene edges) similar to those used in previous network
models (HDN and ODN). Unlike these disease network models, the PSGN uses semantic similarities. This pathophenotypic
similarity has been calculated by comparing pathophenotypic annotations of genes (human abnormalities of HPO terms) in
the ‘‘Human Phenotype Ontology’’. The resulting network contains 1075 genes (nodes) and 26197 significant
pathophenotypic similarities (edges). A global analysis of this network reveals: unnoticed pairs of genes showing
significant pathophenotypic similarity, a biological meaningful re-arrangement of the pathological relationships between
genes, correlations of biochemical interactions with higher similarity scores and functional biases in metabolic and essential
genes toward the pathophenotypic specificity and the pleiotropy, respectively. Additionally, pathophenotypic similarities
and metabolic interactions of genes associated with maple syrup urine disease (MSUD) have been used to merge into a
coherent pathological module. Our results indicate that pathophenotypes contribute to identify underlying co-
dependencies among disease-causing genes that are useful to describe disease modularity.
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Introduction
Phenotypes are the result of the expression of specific genetic
backgrounds submitted to the influence of changing environmen-
tal conditions [1]. Thus, both the development and resulting
symptoms of a given pathology are conditioned by interacting
elements at multiple interconnected levels (from molecular to
social levels) [2]. These complex interactions can be represented as
networks to be analyzed using the principles of Network Theory
[3–6]. In this sense, Network Medicine emerged as a new field to
study the relationships among diseases and disease-causing genes
[7]. Generally, data from genetic association studies establish the
basic information for these analyses. Most of these data are
available from different public repositories, for instance, Online
Mendelian Inheritance in Man (OMIM) [8] and Orphanet [9].
This information can be projected onto networks also known as
diseasomes (i.e. ‘‘the human disease network’’ and ‘‘the orphan
disease networks’’) [10,11]. These diseasomes open the possibility
to work on different types of network projections, treating
networks as graphs, which can be used to detect emergent
information. For instance, disease-to-gene associations represent
bipartite edges (two different types of nodes in every edge) and
conform a bipartite graph (as shown in the schematic represen-
tation in Figure 1A). On the other hand, projections of gene-to-
gene edges and disease-to-disease edges can be inferred from the
initial bipartite graph as two different ‘‘unipartite’’ graphs (each
with only one type of node). Hence, edges in both inferred
unipartite graphs represent either genes associated by a same
disease (Figure 1A) or diseases associated through a same gene
(these edges were not considered in this study), respectively. The
first type of projections (gene-to-gene) are disease-causing gene
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networks and the second ones (disease-to-disease edges) are
generally known as disease networks [10,11]. Network-based
methods enable us to find disease modules that may be understood
as all molecular relationships involving disease-causing genes and
other genes related to the same pathological processes [7]. In fact,
several different biomolecular interactomes based on physical,
metabolic or functional interactions have been used to capture
some frames of the biological complexity associated with
pathologies [12–17]. In this case, one of the most direct
applications of network medicine approaches lies in the systematic
exploration of the molecular mechanism shared by ‘‘apparently’’
distinct diseases [7]. The emergence of relationships among genes
and diseases contribute to obtain more holistic views of the disease
origin and environment, to predict new disease-causing genes [17],
and possibly to locate new targets for disease diagnosis and/or
intervention. All these challenges take part in a wider emergent
discipline known as Systems Medicine [18].
However, current pathognomonic classifications are influenced
by the traditional clinical procedures used during the 19th century
following Oslers principles [19]. These traditional procedures
often tend to overvalue the most evident manifested abnormalities
(pathophenotypes), causing a direct impact on how pathopheno-
typic profiles of patients are registered in the clinic [19]. Although
it could help the diagnosis, many others pathophenotypes will go
unnoticed. As a consequence, most genetic diseases are described
as conceptual entities, pathologies, with certain specific clinical
features. The disregard of pathophenotypes implies a considerable
technical problem for network medicine based methods, since they
can be primary consequences of the genetic disturbances. At
present, to solve this problem standard phenotypic platforms are
required to explore the underlying molecular and cellular
mechanisms related to genetic predisposition in developing
diseases [20]. Nevertheless, some previous works have claimed
that the systematic phenotyping procedure requires ontologies to
improve biomedical insights on functional gene communities [21–
23]. In this case, the use of ontologies can be an interesting
advance in the biomedical integration of this information. The
Human Phenotype Ontology (HPO) represents a formalization of
the semantic relationships [21,24] among different clinical features
described in OMIM (abbreviations used throughout the manu-
script are reported in Table 1). Although HPO was initially
developed to study the phenotypic associations in order to achieve
a potential diagnostic use [25], this standardized biomedical
knowledge on human abnormalities allows the identification of
Figure 1. Schematic representation of distinct disease-to-gene relationships. Different disease associations between genes using (A) the
data from genetic disease databases or (B) their associated pathological phenotypes. (A) The co-associations of genes in disease/s allow the inference
of gene-to-gene projection (unipartite) from the disease-to-gene projection (bipartite). In this case Gene B and Gene C are co-associated with Disease
C. (B) The HPO annotations of genetic diseases allow the description of pathophenotypic space for genes and calculation of the semantic similarity
(pathophenotypic similarity) between them. In this case, novel relationships emerge as occur between Gene A and Gene B or Gene A and Gene C. (C)
The proposed classification in this work: monogenic disease and monotropic genes (MD-MG), monogenic disease and pleiotropic genes (MD-PG),
polygenic disease and monotropic gene (PD-MG), polygenic disease and pleiotropic gene (PD-PG). It is noteworthy that genes present in the MD-PG
subset can also be present in the PD-PG subset (dashed line linked to monogenic disease in grey).
doi:10.1371/journal.pone.0056653.g001
Using Pathological Phenotypes for Human Diseasomes
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functional gene-to-gene relationships involved in similar patho-
logical processes [26]. Recent studies conclude that the phenotypic
similarity measurement proposed by Robinson and co-workers
[25] has a significant contribution to the biological coherence
compared to text-mining methods [27]. Therefore, on the one
hand, the study of the similarity among pathologies requires
representing them as a set of pathophenotypes instead of a
pathological entity. On the other side, pathophenotypic informa-
tion can be used to reinterpret the relationships among diseases
identifying a new pathological phenotypic space that makes it
possible the study of novel gene-to-gene associations (as can be
seen in the schematic representation in Figure 1B). Zhang et al.
[11] have recently stressed some limitations of network-based
methods suggesting that the relationships between rare diseases
cannot be fully captured by gene-to-gene projections alone.
Therefore, the efforts to characterize the genetic and functional
environment of given diseases (disease modules) can contribute to
enrich the usefulness of disease network analyses.
In this work, network medicine approaches have been used to
study the pathological relationships among genes using semantic
similarities (that in this case are pathophenotypic similarities)
instead of inferred unipartite edges (gene-to-gene) from bipartite
edges (disease-to-gene associations). For instance, a classification of
four distinct disease-to-gene associations is proposed (Figure 1C) to
illustrate possible limitations of the current disease-to-gene
network models [10,11]. These classes provide four different
subsets of genes in agreement with the number of genes associated
with a disease (monogenic or polygenic) and the number of
diseases associated with a gene (monotropic and pleiotropic). We
have also built a pathophenotypic similarity gene network (PSGN)
using semantic similarity [25] between genes that are annotated in
HPO. The topological features of gene subsets obtained from
inferred pathological networks have been analyzed and compared
in PSGN. Additionally, the representation of PSGN in three
different human biomolecular interactomes based on physical
interactions, metabolic flux coupling and functional interactions
were also evaluated. For this, a network comparison analysis [28]
and a subsequent performance validation have been used to study
the degree of contribution of each biomolecular interactome to the
biological consistency of gene-to-gene pathophenotypic similari-
ties. In addition, this biological coherence can be used to
incorporate novel components in disease-causing gene modules,
as we demonstrate for maple syrup urine disease (MSUD), an
inborn error of the metabolism of branched-chain amino acids.
Summarizing, this work provides evidence that a standard
phenotypic profiling expands the genetic disease associations using
a specific ontology for human abnormalities. These pathologic
relationships among genes were not obvious and, consequently,
disregarded in previous disease network analyses.
Methods
Unipartite Projections of Current Diseasomes
Human disease causing gene network. In the present
study, we worked on an updated version of the ‘‘Human Diseases
Network’’ (HDN) [10] using Morbid Map from OMIM (http://
www.omim.org/). HDN represents a bipartite projection of edges
with two types of nodes, genes (MIM genes) and diseases (MIM
phenotypes and genes/phenotypes) as described in OMIM. We
followed a similar methodology to the one described by Goh et al.
[10]. We retrieved all disease-to-gene associations where molec-
ular bases are known and we discarded those phenotypes without
MIM numbers. However, unlike previous works [10] we have not
grouped diseases according to the similarity between their names.
Here, each MIM phenotype or MIM gene/phenotype was
considered as a pathological entity and each MIM gene was
transformed to its respective Entrez Gene ID. This new version of
the HDN consists of 2525 genes (Entrez Gene IDs) associated with
3132 OMIM entries (MIM numbers) generating a network of
5657 nodes and 3862 edges (HDN in Table S1). Hence, we built
the respective unipartite projections based on inferred gene-to-
gene relationships, named as human disease causing gene network
(HDGN). This inference provides emergent gene-to-gene edges if
genes are sharing at least one disease.
Orphan disease causing gene network. An updated
version of the ‘‘Orphan Disease Networks’’ (ODN) [11] was built
using Orphanet data. We used Orphanet because it is focused on
genetic and low prevalent diseases; this database is actively
updated and continuously reviewed by clinical experts. ODN is
the bipartite projection of edges with two types of nodes, genes
(Orpha numbers for genes) and orphan diseases (also in Orpha
numbers for diseases). All those genes identified with Orpha
numbers were transformed to Entrez Gene IDs. This new version
of ODN consists of 2331 genes (Entrez Gene IDs) associated with
2125 genetic orphan diseases (ORPHA numbers) generating a
network of 4456 nodes and 3657 edges (ODN in Table S2). In a
similar procedure to that used for HDN (mentioned above), we
built the unipartite projections based on gene-to-gene inferred
relationships for ODN, named orphan disease-causing genes
network (ODGN).
Classification of Disease-to-gene Associations in
Diseasomes
Both HDN and ODN were decomposed into four subclasses,
based on the classification of the different types of disease-to-gene
associations (Figure 1C): monogenic diseases associated with
monotropic genes (MD-MG), monogenic diseases associated with
pleiotropic genes (MD-PG), polygenic diseases associated with
monotropic genes (PD-MG) and polygenic diseases associated with
pleiotropic genes (PD-PG). In the context of the present study, we
use the expression ‘‘monotropic genes’’ to refer to genes that have
been previously related to only one disease and the expression
‘‘pleiotropic genes’’ to refer to genes that have been previously
Table 1. List of abbreviations used throughout the paper.
Abbreviation Description
HPO Human Phenotype Ontology
OMIM Online Mendelian Inheritance in Man
HDN Human Disease Network (bipartite projection)
ODN Orphan Disease Network (bipartite projection)
HDGN Human Disease Gene Network (unipartite projection)
ODGN Orphan Disease Gene Network (unipartite projection)
MD-MG Monogenic Disease and Monotropic Genes
MD-PG Monogenic Disease and Pleiotropic Genes
PD-MG Polygenic Disease and Monotropic Genes
PD-PG Polygenic Disease and Pleiotropic Genes
PSGN Pathophenotypic Similarity Gene Network
PIN Physical Interaction Network
MGN Metabolic Gene Network
FSGN Functional Similarity Gene Network
doi:10.1371/journal.pone.0056653.t001
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related to two or more diseases. Each subclass contains a subset of
genes (Tables S3 and S4 Supplementary material).
Pathophenotypic Similarity Gene Network (PSGN)
The pathophenotype gene network was built using pre-
calculated values of semantic similarities between genes through
the Human Phenotype Ontology (HPO). Previously, we had to
describe the pathophenotypic space for genes as the set of
clinical features (HPO terms) associated with each gene.
Altogether 4669 diseases and 258 genes have direct annotations
of their clinical features in HPO, so these diseases and genes
have a list of HPO terms describing their phenotypic space.
However, the lack of specific HPO terms regarding phenotypic
abnormalities for many disease-causing genes hinders the
explanation of their semantic relationships in the ontology.
Many genes are annotated in the ontology with the sum of all
HPO terms that describe their associated diseases in Morbid
Map. In these cases, we used the file ‘‘gene_to_phenotype.txt’’
(available on HPO website) to link HPO terms and genes. This
file was generated using Morbid Map associations between
genes and diseases. Therefore, clinical features described in
OMIM were translated in a standardized vocabulary of HPO
terms (phenotypic abnormalities) that have been used to define
a pathophenotypic space. As mentioned above, this pathophe-
notypic space for a gene can be directly annotated in HPO or
indirectly annotated by the diseases associated with the gene in
Morbid Map. We used the phenotypic space of genes to
calculate their pathophenotypic semantic similarities with other
genes. Only HPO terms with maximal information were used in
agreement with the ontology properties and distribution of
terms (see semantic similarity calculations section below). We
discarded those branches of the ontology without an explicit
description of phenotypic abnormalities such as ‘‘mode of
inheritance’’ and ‘‘onset and clinical course’’. We obtained a
large pathophenotype gene network based on all semantic
similarities between genes sharing HPO terms annotated in the
phenotypic abnormality branch of the HPO. Despite an
extensive literature review we could not detect a systematic
methodology to calculate a cut-off score distinguishing between
relevant or non-specific semantic similarities. Previous works
used the semantic similarity to validate predictions or to
evaluate shared biological features between highly specific subset
of genes. However, in this case, we needed an optimal statistical
threshold from which the signals, pathophenotypic similarities,
should be out of the background noise. The cut-off will
predetermine the topology of the network, so it could affect
arguments and discussion about the ‘‘expansion’’ of pathophe-
notypic relationships respect to current unipartite projections
(HDGN and ODGN). If we select a low similarity score we will
introduce exponentially nonspecific relationships. In contrast, a
very high score will constraint the model to already known
pathological relationships. Therefore, we used the subset of
known pathophenotypic similarities (gene pairs) in a binary
classification system to estimate the optimal statistical threshold
(see supplemental methods and discussion in Methods S1).
Finally, the number of unspecific similarities was reduced by
selecting the cut-off at the 98th percentile that corresponds to
the top 2% of significant gene pairs with higher semantic
similarity values. To assess this clustering process of PSGN in
the top 2% of phenotypic similarity, we plotted a kernel density
distribution of probability of the pathophenotypic similarity for
gene pairs (Figure 2).
Biomolecular Interactomes
Physical interaction network (PIN). We used the CRG
Human Interactome as the reference for physical interaction
network (PIN). This network of protein-to-protein physical
interactions contains 10299 genes (Ensembl gene IDs) and
80922 interactions supported by evidence from at least one
experiment [29]. The topological analysis of the largest connected
component of the CRG Human Interactome was carried out
under a similar procedure to that described in previous published
works [30,31]. However, all Ensembl gene IDs were transformed
to Entrez Gene IDs to enable a node degree correlation and
network comparison analysis with PSGN.
Metabolic gene network (MGN) based on metabolic flux
correlations. Metabolic networks are usually based on different
metabolic coupling approaches such as metabolite sharing (for
instance, shared metabolites between enzymes) [15,32,33] and
metabolic flux correlations (for instance, correlated metabolic
enzymes by flux balance analysis) [34]. In this work, we used the
flux-coupling metabolic network built by Veeramani et al. [34].
This network is based on the results of a flux balance analysis [34]
of an updated version of the Human Metabolic network Recon 1
[35]. We built MGN using only these gene-to-gene interactions
exceeding a metabolic flux correlation value of 0.1 and a
‘‘metscore’’ of 0 from the original network (Table S5, supplemen-
tary material).
Functional similarity gene network (FSGN) based on
biological processes. The FSGN was built by using the
measurement of the semantic similarity between genes described
in the branch of biological processes of the Gene Ontology (GO).
The functional space of a gene is represented by the set of GO
annotations about the biological context where the gene is
involved. Thanks to these annotations, genes are directly linked
to biological processes describing all the functional features direct
or indirectly related to genes. Classical semantic similarity
measurements were used to calculate functional similarities
between genes according to their functional space. In a similar
procedure used for PSGN we removed unspecific functional
associations in FSGN generated by irrelevant semantic relation-
ships. However, there are great differences in the number of
annotations between HPO and the branch of biological processes
of GO. In this case, the main concern is that it resulted in huge size
of this dataset. Therefore, we preferred to be quite more restrictive
for this threshold, by taking as cut-off the 99.5th percentile instead
of the 98th. Thus we selected the top 0.5% of gene pairs with
higher functional similarities (Figure S1).
Semantic Similarity Score Calculations (Gene-to-gene)
The way to assign terms to objects is to add annotations. In the
present case, the objects represent genes and terms corresponding
to phenotypes (HPO terms) or biological processes (GO terms).
The specificity of the terms associated with genes allows us to
calculate the most significant relationships between them, which
use to be related to its proximity to the root. The method we have
chosen to calculate the semantic similarity between objects
annotated is mainly based on the classical Resnik’s measurement
[36]. This approach uses the information content (IC) concept that
is a way to estimate the specificity of a term [25] and can be
defined as the negative natural logarithm of the probability of a
term
IC tð Þ~{logp tð Þ ð1Þ
where p(t) is defined on the basis of its frequency (number of term
annotated) and the total of terms annotated in the ontology.
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p tð Þ~ annotations tð Þ
total annotations
ð2Þ
If the probability decreases then the information content increases
and consequently the specificity and the informativeness increase
too. Thus, the IC tends to increase as we move away from the root
to more specific terms.
For t1 and t2 terms in the ontology, the semantic similarity
proposed by Resnik is defined as:
sim t1,t2ð Þ~ max
p[S t1, t2ð Þ
IC pð Þ ð3Þ
where S(t1,t2) is the set of the shared parents of t1 and t2. In other
words, the semantic similarity between two terms corresponds with
the information content of the most informative common ancestor
(MICA) [36].
Functional Semantic Similarity. Many studies so far have
made a comparison between semantic similarity measurements
using the Gene Ontology, but it seems that there is not a gold
standard for semantic similarity measures between set of GO
terms. In this work we use:
sim g1,g2ð Þ~ max
ti[g1tj[g2
sim ti,tjð Þ ð4Þ
a measurement that has been successfully used in some previously
published works [37,38]. In (4) g1 and g2 represent genes, where
each one is related with a set of ontological terms. The semantic
similarity value between sets of terms is calculated by comparing
each pair of terms (3), one term of each set, and determined from
the maximum value of all pair comparisons.
Pathophenotypic Semantic Similarity. Human Phenotype
Ontology is still a novel tool and there are not many works related
to the calculation of semantic similarity for this data structure. We
have chosen the method proposed by the HPO creators for the
comparisons between phenotypic profiles [25]. For g1 and g2 two
genes; their semantic similarity is defined as:
sim g1,g2ð Þ~ 1
Dg1D
X
ti[g1
max
tj[g2
sim ti,tjð Þ
" #
ð5Þ
where firstly is calculated the maximum value of IC, using the
equation (3), between each term of g1 and the terms of g2. Finally,
a set of values |g1| are used to work out their average.
The previous equation does not provide a symmetric matrix,
since the calculated semantic similarity between g1 and g2 will not
be the same as semantic similarity between g2 and g1, so Robinson
and co-workers [25] suggest a symmetric version:
simsymmetric g1,g2ð Þ~ 1
2
sim g1,g2ð Þz 1
2
sim g2,g1ð Þ ð6Þ
Figure 2. Probability density function for pathophenotypic similarities among pairs of genes in HPO. Densities of the pathophenotypic
similarity values for all annotated genes in HPO (outer plot) and for the top 2% of gene pairs with the highest pathophenotypic similarities (inner
plot). The bandwidth used was 0.01 and the pathophenotypic similarity value for the cut-off at the top 2% was 1.8179.
doi:10.1371/journal.pone.0056653.g002
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Statistical Computing and Network Based Methods
All statistical computing, data management and graphics were
performed in R, a free software environment. Network visualiza-
tions and their metadata analyses were performed in Cytoscape
[39] and iGraph software, an R package (http://igraph.
sourceforge.net/). Due to the large number of subsequent analysis
of all built network, we provided a schematic workflow of all the
essential steps followed for this study (Figure S1).
Network comparison analysis. Once all networks were
built, we carried out a network analysis comparison to compute
the nodal and edge intersection between PSGN and the rest of the
built networks (HDGN, ODGN, PIN, MGN and FSGN). In the
case of disease-causing gene networks (HDGN and ODGN
unipartite projections of diseasomes), the intersection could
provide a broad view of the similarity of these networks and the
PSGN. Previously, we also calculated the intersection of edges
between HDGN and ODGN to assess their mutual similarity. For
biomolecular interactomes (PIN, MGN and FSGN) the nodal and
edge intersection can be useful to explore the underlying
molecular events of pathophenotypic similarities. However,
biomolecular interactomes require two steps before the intersec-
tion analysis. First, we filter networks to ensure that both
compared networks have only intersected nodes to minimize their
differences in sizes (see schematic diagram of the process in Figure
S1). All biomolecular interactomes were filtered to have genes with
pathophenotypic data. Hence, we generated three biomolecular
sub-networks that contain uniquely genes (nodes) participating in
PSGN (Figure S1 and Table S6). This first step was essential for a
more accurate value of the significance in the mutual coverage and
to reduce the noise in the intersected edges. Moreover, this
problem is bidirectional, so we used three different filters for
PSGN (one for each cellular network). It will merge in three PSGN
sub-networks (Figure S1 and Table S6). To evaluate the
significance of the network comparison, we compared PSGN
sub-networks with their respective randomized biomolecular
interactome, treated and filtered exactly as the original networks.
These randomizations were carried out preserving the node
connectivity distribution in the respective cellular networks.
Subsequently, we used NeAT [28] to compare networks treated
as undirected ones. We used different metrics to identify the
significance of the intersection: Maximal number of edges in the
union, Jaccard coefficient and hypergeometric probability (p-
value) [28,40].
Network topological analysis. All gene (node) degrees were
calculated for each pathological network and biomolecular
interactome, using the iGraph software. Subsequently, a non-
parametric test was used to study in each subset of genes the
distributions of the node (gene) degree, the number of associated
pathophenotypes per gene and the mean value of pathophenotypic
similarity per gene. More precisely, a Mann-Whitney test was used
to assess the significance of these distributions for gene subsets with
the distributions of all genes in PSGN and their respective disease-
causing gene network. This non-parametric test was run 1000
times for every subset of genes using a different random sample in
each test. These random samples conserved the same size (number
of genes) as their respective subset in the correspondent network.
Subsequently, we calculated the mean p-value of all runs for every
subset. Additionally, a Spearman’s rank correlation test (a=0.05)
was used to analyze the degree of genes in HDGN, ODGN, PIN,
MGN and FSGN with respect to the number of pathophenotypic
relationships in PSGN.
Performance validation and ROC calculations. A binary
classification system was used to analyze the performance of
intersected interactions between different cellular networks (PIN,
MGN, FSGN) and phenotypic interactions in PSGN. This binary
classification is based on signal detection theory, using a receiver
operating characteristic (ROC) analysis [41]. We compared
biomolecular interactomes and their respective randomized
versions (similar to those ones used in the network comparison
analysis) with the PSGN using phenotypic similarities as the value
of the signal (Figure S1). ROC curves were obtained considering
the intersected interactions of PSGN with biomolecular inter-
actomes as True Positives and those of PSGN with random
biomolecular interactions as False Positives (Figure S1). We used
randomizations to generate a dataset of False Positives propor-
tional to the number of obtained True Positives for each
biomolecular interactome. This procedure was useful to increase
the confidence of the ROC analysis. In addition, we calculated the
average area under the curve (AUC) for each interactome,
calculating about 20 ROC curves following this same procedure.
Results and Discussion
Comprehensive Classification of Disease-to-gene
Associations Contained in Currently Available
Diseasomes
The projection in networks of the genetic associations data,
available in OMIM and Orphanet, shows different patterns of
connectivity among diseases and mutated genes (Figure 1A). Thus,
we proceeded to build updated versions of existing models of
disease networks, the ‘‘human disease network’’ (HDN) [10] and
the ‘‘orphan disease network’’ (ODN) [11]. Subsequently, we
classified all disease-gene associations of HDN and ODN in order
to get an insight regarding their global distribution. For this
purpose, we retrieved a total of 2525 and 2331 genes from HDN
and ODN, respectively. Each gene dataset was subdivided in four
different classes (Tables S3 and S4 for HDN and ODN
respectively) according to our proposed criteria (Figure 1C): two
monotropic classes (MD-MG and PD-MG) and two pleiotropic
classes (MD-PG and PD-PG). Monotropic subsets are exclusive
because their relationship with the disease is unique so genes take
part in only one subset and they represent 72% and 69% of the
total genes in HDN and ODN, respectively. In contrast,
pleiotropic genes can be related to monogenic as well as to
polygenic diseases so they can be present in both pleiotropic
subsets.
The abundance of genes in each subset indicates how genetic
association studies tend to distribute genes with different degrees of
specificity for pathologies. In both networks, monotropic genes are
found to be the most abundant ones, irrespective of the actual
number of genes involved in the diseases (Table 2). For instance,
‘‘biunivocal’’ genes (MD-MG subset genes) represent over 56%
and 30% of HDN and ODN genes respectively (Table 2). Even
more, genes included in the PD-MG class are the most abundant
ones in orphan disease network reaching 39% of the total genes.
Many PD-MG associations could involve highly co-regulated
genes (i.e. coding genes for different subunits of multi-protein
complexes), so these genes can be considered a whole functional
unit. In this case, we suspect that biunivocal relationships might be
underestimated.
The ratios of diseases per gene agree with a pathological
convergence (exclusive associations) and divergence (non exclusive
associations) for monotropic and pleiotropic genes respectively
(Table 2). These results are obvious taking into account our
classification criteria. However, they provide a panoramic view of
how a set of clinical features (pathophenotypes) observed in
patients reach consensus and are attributed to a disease. These
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results seem to show a human annotation bias that can affect the
current disease classifications.
Features of Disease Causing Gene Networks (Unipartite
Projections)
From the bipartite projections (disease-to-gene) of HDN and
ODN, we built their corresponding unipartite projections (gene-to-
gene) (as can be seen in Figure 1A), named as ‘‘human disease
causing gene network’’ (HDGN) and ‘‘orphan disease causing gene
network’’ (ODGN) respectively (Figures 3A and 3B). Both
unipartite projections are based on the emergence of gene-to-
gene relationships (edges) inferred from pair of genes co-associated
with at least one disease (Figure 1A). Accordingly, all genes in the
MD-MG subsets and those uniquely associated with monogenic
diseases in MD-PG will appear as unconnected genes in unipartite
projections (HDGN and ODGN).
HDGN include 749 genes (nodes) and 2654 inferred gene-gene
relationships (edges) among them (Figure 3A and Table S1).
However, ODGN is twice as larger as HDGN with 1492 genes
and 6380 inferred gene-gene relationships (Figure 3B and Table
S2). At first glance, the topological structures of unipartite
networks (HDGN and ODGN) are quite similar (Figures 3A and
3B) although an enrichment of unconnected nodes in HDGN is
clear when compared to ODGN (1776 and 839 for HDGN and
ODGN respectively). This enrichment is mainly due to the higher
number of biunivocal relationships (MD-MG) in HDGN (Table 2).
Therefore, this is the reason why HDGN shows fewer inferred
relationships (2654) than ODGN (6380).
We carried out an analysis of the intersection between both
unipartite networks (HDGN and ODGN) to assess an estimation
of their similarity. But first we removed all unconnected nodes
because they were not considered structural components of these
networks. The resulting intersection was 481 genes (intersected
nodes) and 662 inferred gene-gene relationships (intersected edges)
corresponding to 24% and 10% of edges in HDGN and ODGN
respectively (Table 3). Both networks show a Jaccard coefficient of
similarity (number of edges in the intersection divided by the
number of edges in the union) of 7.9% (Table 3). Surprisingly, the
similarity is lower than expected a priori which indicates strong
differences between the two data sources (OMIM and Orphanet).
These results reinforce the hypothesis that the absence of a
systematic procedure in the phenotypically characterization of
genetic diseases will affect the utility of network medicine methods.
In particular, it leads to the isolation of genes and diseases from
their real pathological processes, making it practically impossible
to identify groups or subgroups of related pathologies. This
observed tendency to the exclusiveness (that is to say, the
abundance of monotropic gene-disease relationships) considerably
increases the disease-gene association specificity that may be of
interest for genetic testing.
Features of Pathophenotypic Similarity Gene Network
(PSGN)
The exclusiveness mentioned above could affect pathological
processes with many disease variants. In the case of these diseases,
Table 2. Distribution of disease-to-gene associations on
proposed classification.
Human Diseases Network Orphan Disease Networks
Subset Diseases per geneGenes (%) Diseases per geneGenes (%)
MD-MG 1.00 1431 (56.7) 1.00 717 (30.8)
MD-PG 2.57 639 (25.3) 2.71 435 (18.7)
PD-MG 0.46 379 (15.0) 0.40 908 (39.0)
PD-PGa 2.13 371 (14.7) 1.68 584 (25.1)
All genesb 1.24 2525 (100) 0.91 2331 (100)
aPleiotropic genes associated with at least one polygenic diseases.
bAll genes in HDN and ODN respectively.
doi:10.1371/journal.pone.0056653.t002
Figure 3. Unipartite gene-to-gene projections of the disease networks and the pathophenotypic similarity gene network. Human
diseases genetic network (HDGN in panel A), Orphan diseases genetic network (ODGN in Panel B) and Human pathophenotype similarity gene
network (PSGN in panel C). PSGN consists of one connected component (with a few unconnected genes), in contrast to HDGN and ODGN that show a
great variety of isolated patterns of association. All unconnected genes (nodes) correspond to those uniquely associated with monogenic diseases, all
of them were excluded in unipartite projections.
doi:10.1371/journal.pone.0056653.g003
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some genes play a primary role in the progression of the pathology
but others modulate the phenotypic variability.
To tackle this problem, HPO offers possibilities for a formal
study of the pathophenotypic relationships among genes on the
bases of their semantic similarities (pathophenotypic similarities).
Therefore, we defined the pathophenotypic space of each gene,
consisting of the set of HPO terms associated with the gene (as
shown in Figure 1B). These spaces were described using only
specific HPO terms, those farthest terms from the root of the
ontology, to calculate the semantic similarity value between every
two given genes (see methods, Table S7). Higher values of
semantic similarity indicate greater specificity in the common
pathophenotypic space between a pair of genes. It is known that
ontology-based phenotypic similarity methods can also contribute
to improve disease-causing gene networks based on phenotypic
information built with text-mining analysis [42] or random-walk
trajectories between genes considering the ontology as a simple
graph [43].
From all calculated pathophenotypic similarities greater than
zero, we selected the top 2% of more significant pairs of genes.
This selection provides the pathophenotypic similarity gene
network (PSGN) with 1075 genes and 26197 gene-to-gene
pathophenotypic similarities (Figure 3C and Table S7). Disease-
causing gene networks (HDGN and ODGN) exhibit explicit
structural differences when they are compared to PSGN (Figure 3);
for instance, PSGN consists of only one giant connected
component (Figure 3C), which is not the case for HDGN and
ODGN.
Almost all the pathophenotypic gene annotations used in HPO
originally come from OMIM and they represent the sum of all
clinical features of diseases associated with a gene. Accordingly,
the pathophenotypic similarity for a gene is somehow dependent
on the number of diseases associated with this gene (see methods
section). Hence, we proceed with a comprehensive study to assess
whether the pathophenotypic similarity can be used to reinterpret
the pathological relationships between genes (see supplementary
methods and discussion in Methods S1).
Pathophenotypic Similarity Reveals a New
Understanding of Pathological Relationships
The survey of the mutual coverage between PSGN and each
unipartite projection (HDGN and ODGN) was carried out with an
analysis of their intersections.
The resulting intersections of PSGN with each unipartite
projection proved 528 shared nodes and 1055 shared edges for
HDGN and 931 and 1669 for ODGN (Table 4). Therefore, 39%
and 26% of inferred pathological relationships intersect with
pathophenotypic similarities of PSGN, even improving the
intersection between disease causing gene networks (mentioned
above). The Jaccard coefficient of similarity of the intersection of
PSGN with each pathological network was 3.8% and 5.4% for
HDGN and ODGN respectively (Table 4). This can be considered
an interesting performance value if we take into account the
dependence on the Jaccard coefficient on the different sizes of
compared networks (the number of edges in the union are 27796
for HDGN and 30908 for ODGN). Furthermore, there are about
25000 new pathophenotypic similarities, excluding inferred
pathological relationships, to be used for the discovery of new
underlying pathological relationships among genes.
Topological analysis exhibits the emergence of unnoticed
pathological relationships. We have also studied how genes
in PSGN are distributed in comparison to HDGN and ODGN.
Subsequently, we analyzed the degree distribution of genes for
each network (HDGN, ODGN and PSGN), as well as for their
respective gene subsets (MD-MG, MD-PG, PD-MG and PD-PG
of HDN and ODN). We carried out a Mann-Whitney test to assess
the significance of the difference of the degree distribution of each
subset in their respective disease-causing gene network and in
PSGN (Figure 4, a boxplot was used in all the cases). In agreement
with our classification criteria, MD-MG genes (bi-univocal) have
null connectivity in their respective disease-causing gene networks
(Figure 4A). By contrast, MD-MG genes are phenotypically linked
to a mean of 25 genes in PSGN indicating an expansion of
pathophenotypic relationships between disease-causing genes in
PSGN (Figure 4B). In pathological networks, degree distributions
are significantly different for ODGN subsets (PD-MG and PD-PG)
but not for HDGN subsets (see their correspondent p-values in
Figure 4A). On the other hand, degree distributions in PSGN are
quite similar when compared to the equivalent subsets of HDGN
and ODGN, where higher node degree for pleiotropic genes and
lower for monotropic genes can be appreciated (Figure 4B). In
addition, Spearman’s rank correlation test was used to explore
degree correlations between the pathophenotypic similarity
(PSGN) and disease-causing gene networks (HDGN and ODGN)
(Table S8). Weak (but statistically significant) positive correlations
were found between gene pathological and pathophenotypical
relationships (Table S8). These results, as shown in Figure 4 and
Table 3. Network intersection analysis between HDGN and
ODGN.
Network features Values
Number of nodes in HDGN 749
Number of nodes in ODGN 1492
Number of edges in HDGN 2654
Number of edges in ODGN 6380
Observed nodes in the intersection 481
Observed edges in the intersection 662
Percentage of edges in HDGN 24.94
Percentage of edges in ODGN 10.38
Jaccard coefficient of similarity 0.079a
aFraction of edges in the intersection respect to the total edges in the union.
doi:10.1371/journal.pone.0056653.t003
Table 4. Network intersection analysis between PSGN and
HDGN or ODGN.
Network features HDGN values ODGN values
Number of nodes in PSGN 1705 1705
Number of nodes in pahtological network 749 1492
Number of edges in PSGN 26197 26197
Number of edges in pahtological network 2654 6380
Observed nodes in the intersection 528 931
Observed edges in the intersection 1055 1669
Percentage of edges in PSGN 4.03 6.37
Percentage of edges in pahtological network 39.75 26.16
Jaccard coefficient of similarity 0.038a 0.054a
aFraction of edges in the intersection respect to the total edges in the union.
doi:10.1371/journal.pone.0056653.t004
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Table S8, clearly show that gene degrees in pathological networks
differ from those calculated using pathophenotypic similarities.
The (apparently) most striking observation is that genes
uniquely associated with monogenic diseases (genes in MD-MG
and many of MD-PG) are present in PSGN. The vast majority of
these genes appeared as unconnected genes in the unipartite
projections of HDN and ODN (as shown in Figure 3). This means
that pathophenotypic similarities lead to the emergence of novel
relationships that remained hidden in the gene-to-gene projections
of current diseasomes.
Specific contribution of gene subsets to gene-to-gene
pathophenotypic similarities. In light of the result discussed
above, we consider it necessary to prove the contribution of each
type of gene subset to the gene-to-gene similarities of PSGN. This
could help to unveil the relationship between the pathological
convergences or divergences and the pathophenotypic similarities
[30]. Therefore, we analyzed the abundance of pathological
phenotypes and the average pathophenotypic similarity per gene.
Figure 5 (panels A and B) represents the distribution of the
abundance of pathophenotypes (HPO terms) in genes for HDN
and ODN subsets. Pleiotropic genes show distributions signifi-
cantly different to the distribution of all genes included in PSGN
using a Mann-Whitney test (see their correspondent low p-values
for MD-PG and PD-PG, Figure 5 panels A and B). On the other
hand, monotropic genes seem to be well represented in the
pathophenome (whole genes of PSGN) showing only slight
differences in the distribution of PD-MG subset for ODN (see
the p-value for PD-MG in Figure 5B). Consequently, we can be
confident that the phenotypic descriptions used for monotropic
genes are not underestimated and they are enough to calculate
their pathophenotypic similarities to other genes. By contrast, as
expected, pleiotropic genes tend to be annotated in the ontology
with more clinical features compared to the whole gene
annotations. For an overall estimation of how each subset
contributes to the pathophenotypic co-dependence between genes,
we calculated the average of pathophenotypic similarity values
associated with each gene in the PSGN in order to compare their
distributions in different subsets (Figures 5C and 5D). The
monotropic subsets contain genes with the highest specific
relationships to diseases. Nevertheless, monotropic subsets show
very different behavior compared to all genes of the PSGN in the
distribution of the average pathophenotypic similarities related to
genes within HDN and ODN subsets (see the low p-values for
MD-MG and PD-MG in Figures 5C and 5D). MD-MG subsets
show lower average pathophenotypic similarity values (Figures 5C
and 5D). As a result, these distributions also reveal pathopheno-
typic relationships among genes that remained lost in the gene-to-
gene unipartite projections of HDN and ODN. The distributions
of PD-MG subsets show higher average phenotypic similarities
between genes (observe that the green curves in Figures 5C and
5D are displaced to the right when compared to the respective red
curves, as well as to the rest of curves). This observation could be
mainly due to the fact that they are sharing similar sets of
annotations, and in many cases they are functional units or
strongly co-regulated molecular complexes. With regards to
pleiotropic subsets, they seem to be slightly affected by the
number of genes involved in the disease (monogenic and
polygenic). Nonetheless, their abundance of pathophenotypes
could increase the number of non-specific relationships between
genes. In this case, non-specific relationships will tend to show low
values of similarities decreasing the average value associated with
genes. In fact, this agrees with the higher connectivity observed for
pleiotropic subsets in both HDN and ODN (Figure 4). For this
reason, we analyzed the degree of association between the
abundance of pathophenotype per gene and the average similarity
value per gene. A weak Spearman correlation was obtained (p-
value 1.8E226 and rs=20.25, Figure S2) so we can ensure no
clear dependence between both parameters. However, there is a
tendency to decrease the mean value of pathophenotypic similarity
for genes with abundant HPO terms annotations.
Apparently, the use of semantic similarity measurements
produces a rearrangement in the pathophenotypic co-dependence
between genes overcoming the bias that can be introduced from
the original source of data, the Morbid Map. However, the gene
pleiotropy dampens their average pathophenotypic similarity
values indicating a rise of unspecific relationships with other genes
compared to monotropic genes. This observation reinforces our
suggestion that the representation of diseasomes as unipartite
projections is insufficient to study other underlying (and not
necessarily obvious) pathophenotypic relationships.
Overview of the Relationship between Metabolic or
Essential Genes and Pathophenotypic Similarity
Taking into account that metabolic and essential disease genes
represent about 18% and 34% respectively of the total disease-
causing genes, we also studied how they are represented in each
subset of genes in our classification (Table 5). The subsequent
study of cumulative frequencies per gene of the associated
pathopenotypes (Figure 6A) and the average pathophenotypic
similarity values (Figure 6B) suggest that gene subsets tend to be
associated with different biological properties.
Enrichment of metabolic genes in the MD-MG
subclass. Biunivocal classes (MD-MG) are markedly enriched
in metabolic coding genes with respect to the other classes; on the
contrary, PD-MG is underrepresented by metabolic enzymes. On
the other hand, the pathophenotypes corresponding to metabolic
genes do not differ from those of the whole pathophenome (see
non-significant p value in Figure 6A). However, the mean value of
phenotypic similarity is lower for metabolic genes than for the
whole pathophenome (Figure 6B). For instance, metabolic genes
tend to be involved in more specific pathological processes and
exclusively related to pathophenotypes recognized as genetic
diseases. It seems relevant that metabolic genes are mainly
enriched in the MD-MG subset: 67% and 49% of the whole set
of genes in MGN are MD-MG for HDGN and ODGN,
respectively. In addition, metabolic genes show a lower distribu-
tion of the mean values of pathophenotypes compared to the
whole pathophenome (Figure 6). Therefore, dysfunctions in
metabolic genes prove a functional bias in disease and gene
association studies toward the pathophenotypic specificity
(Figure 6). At least two factors could contribute to explain this
observation: first, the molecular basis of metabolic dysfunctions
can be more precisely identified in these diseases; second, these
diseases exhibit pathophenotypes with highly distinguishable
features. In any case, both factors can be influenced by the
application of routine biochemical analysis in the clinical setup,
which allows an easier detection of abnormal concentrations of
metabolites in blood or urine.
Figure 4. Degree distribution of subset genes in pathological and pathophenotypic gene-to-gene networks. Box plots of the degree of
subset genes in HDGN (blue) and ODGN (red). Box plots of the degree of subset genes in PSGN for ODN subsets (blue) and for ODN subsets (red). In
bold and red, significant p-values. (*) Mean values. (#) Subsets of completely unconnected genes.
doi:10.1371/journal.pone.0056653.g004
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Enrichment of essential genes in the pleiotropic
subsets. Zhang et al. [11] have reported an enrichment of
essential genes in ODN with respect to HDN but our results
suggest that both networks show a similar proportion of essential
genes (Table 5). In particular, the results shown in Table 5 also
indicate that an enrichment of essential genes is produced in
pleiotropic gene subclasses. The number of pathophenotypes
associated with essential genes is significantly higher than that
obtained when using all genes in the PSGN (Figure 6A). But their
distribution of mean values of phenotypic similarities is statistically
indistinguishable from that of the whole pathophenome
(Figure 6B). Some previous network medicine works have
discussed how essential genes are represented in different
diseaseomes [10,11,30]. Barabasi and co-workers concluded that
disease-causing genes are not essential genes because their
associated lethality could have severe consequences [10]. Chavali
et al. [30] proposed two different topological features for
phenotypically divergent genes and essential disease genes, inter-
modular and intra-modular hubs respectively. Zhang et al. [11] in
their analysis of the orphan disease network found that ODs are
enriched in essential genes as compared with the whole set of
diseases. In contrast, when we compared the same essential gene
dataset used by these authors in the updated versions of HDN and
ODN, no detectable differences were found (Table 5). Our
observation differs from that of Zhang et al. [11], maybe due to
the use an updated version of both disease-causing gene networks
and the same dataset of essential genes. In any case, our results do
not support the idea that there could be a negative correlation
between gene essentiality and disease prevalence. Nonetheless, it
seems that there is a certain enrichment of essential genes in the
Figure 5. Distributions of the number of pathophenotypes and pathophenotypic similarities in each subset. MD-MG (red line), MD-PG
(orange line), PD-MG (green line), PD-PG (blue line) and PSGN (Black line). Upper panels represent the cumulative frequency of the number of specific
pathophenotypes annotated for genes in HDN (C) and ODN (D) subsets, the whole set of genes in HPO (PSGN) was used as the reference distribution.
Lower panels represent the cumulative frequency of the average pathophenotypic similarity associated with genes in HDN (C) and ODN (D) subsets,
the whole set of genes in HPO (PSGN) was used as the reference distribution. The p-values, included in each legend, represent the mean of the
resulting p-values after 1000 non-parametric tests (Mann-Whitney test) where each subset was compared, each time, with a random sample of the
pathophenome of the same size of the subset (see methods).
doi:10.1371/journal.pone.0056653.g005
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Figure 6. Distributions of the number of pathophenotypes and the pathophenotypic similarities for metabolic and essential genes.
Metabolic genes (orange line), essential genes (orange line) and the PSGN (Black line). Upper panel (A) represents the cumulative frequency of the
number of specific pathophenotypes annotated for genes, the whole set of genes in HPO (PSGN) was used as the reference distribution. Lower panel
(B) represents the cumulative frequency of the average pathophenotypic similarity associated with genes, the whole set of genes in HPO (PSGN) was
used as the reference distribution. The p-values, included in each legend, represent the mean of the resulting p-values after 1000 non-parametric
tests (Mann-Whitney test) where every set of metabolic and essential genes was compared, each time, with a random sample of genes in PSGN of the
same size of their respective set (see methods).
doi:10.1371/journal.pone.0056653.g006
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subsets of ‘‘pleoiotropic’’ genes, that is, those associated with more
than one disease (Table 5). This result agrees with observed by
Chavali et al. in the dataset of shared genes by diseases [30]. The
dataset of essential genes used in these works [10,11,30] are
human orthologous of lethal mouse genes catalogued in the Mouse
Genome database [44].
From our point of view, the enrichment of essential genes in
pleiotropic disease-causing genes leads to interesting evolutionary
questions on how mutations in these genes are related to their
lethality for other mammals and might be involved in the limits of
human evolvability [45,46].
Integrative Analysis of PSGN
Built biomolecular interactomes (PIN, MGN and
FSGN). The heterogeneity of the cellular interactions among
genes affects (either directly or indirectly) the progression of the
diseases [13]. Thus, the disturbances caused by genetic mutations
can be transmitted in biological systems in several distinct ways.
Three different biomolecular interactomes were built to study the
association between the pathophenotypic similarity and each type
of biological interaction (physical, metabolic and functional
interactions). PIN results in 9580 genes connected through
74657 physical interactions (Table S5). MGN contains 535
enzyme-coding genes interconnected by 9812 flux correlations
(Table S5). The top 0.5% of functional similarities in the branch of
biological processes in the Gene Ontology corresponds to FSGN.
FSGN results in 9157 genes and 496973 significant functional
similarities (Table S5). For each biomolecular interactome, we
evaluated their coverage in PSGN and the contribution of each
type of biological interaction to the score of pathophenotypic
similarity.
Network comparison analysis between biomolecular
interactomes and PSGN. ‘A network intersection analysis
was carried out using the PSGN as reference and the biomolecular
interactomes (PIN, MGN or FSGN) as queries. Nevertheless, the
observed differences in size and density of the studied networks
could be the cause that the direct network comparison analysis
would provide no useful significance values. Therefore, we decided
to standardize the contents of the networks by using the
intersection of nodes (see methods section) to minimize differences
between the reference (PSGN) and the rest of the networks (PIN,
MGN or FSGN). This step (Figure S1) provoked a strong
structural decomposition from all the original networks that
resulted in sub-networks (Table S6). Although we reduced the size
differences between the intersected networks, other features are
still preserved like the density of edges, which are inherent to the
nature of each network (Table 6).
The network comparison results show statistically significant
intersections of edges for all biomolecular interactome sub-
networks compared to their respective PSGN sub-network
(Table 7). This was not the case for randomized networks used
as negative controls. The hypergeometric test shows a lower
significance of the pathophenotypic similarities resulting in the
intersection between PSGN and MGN when compared to PIN
and FSGN (Table 7). Nevertheless, the Jaccard coefficient of
similarity between biomolecular interactomes and their respective
PSGN sub-network was higher for MGN and FSGN (9.8% and
5.4% respectively) than for PIN (2.5%). In this sense, both the
percentage of edges remaining in the reference sub-network and
the Jaccard coefficient of similarity seem to be good indicators of
the size of the phenotypic space covered by the intersection
(Table 7). The 23.7% of physical interactions between diseases-
causing genes match with pathophenotypic similarities, 11.7% and
8.1% for metabolic flux correlation and functional interactions
respectively. FSGN showed the largest and most significant
coverage in PSGN (Table 7), which means that the functional
relationships of genes based on biological processes define the
broadest context of the molecular mechanisms associated with
disease-causing genes. Concerning biochemical interactomes (PIN
and MGN), PIN exhibits a greater coverage of genes at the
intersection than MGN, although the latter presents the highest
Jaccard coefficient of similarity (Table 7).
Specific contribution of biomolecular interactions to
pathophenotypic similarities. Most of the published network
biology studies have made use of the degree of a node (number of
connections with other nodes) to assess its relevance in a network.
In fact, node degree has been extensively used in physical
interaction networks [10,11,30,31] but also in metabolic networks
[15,32]. In this work, a topological analysis was carried out in
different biomolecular interactomes to calculate the degree of
genes (based on gene-to-gene interactions).
To estimate whether the abundance of biological interactions
for genes is correlated with the number of phatophenotypic
similarities in PSGN, we carried out a Spearman’s rank
correlation test of gene degrees. This test showed weak, but
statistically significant, positive correlations between gene degrees
for the whole set of genes (p-value = 2.0E207, r = 0.15 for HDN;
p-value = 3.2E208, r = 0.16 for ODN) when PIN was compared
to PSGN. No significant correlations were found when either
MGN or FSGN were compared to PSGN (Table S9). The values
Table 5. Distribution of essential and metabolic genes in current diseases network.
HDN ODN
Essential Metabolic Essential Metabolic
Subset genes (% in class) genes (% in class) genes (% in class) genes (% in class)
MD-MG 409 (28.6) 308 (21.5) 219 (30.5) 202 (28.2)
MD-PG 315 (49.2) 79 (12.4) 228 (52.4) 64 (14.7)
PD-MG 106 (28.0) 65 (17.2) 245 (27.0) 105 (11.6)
PD-PGa 189 (50.9) 34 (9.2) 286 (49.0) 73 (12.5)
All genesb 856 (33.9c) 458 (18.1) 802 (34.4c) 409 (17.6)
We determined for each class the percentage of genes considered as essentials and metabolic coding genes included in the built metabolic network (MGN).
aPleiotropic genes associated with at least one polygenic diseases.
bAll genes in HDN and ODN respectively.
cMinimal changes are seen compared to Zhang et al.(2011) [11], these differences are due to updating of data Orphanet.
doi:10.1371/journal.pone.0056653.t005
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for the different subsets obtained in this analysis clearly show that
only physical interactions bear some relation with the abundance
of pathophenotypic similarities in pleiotropic genes associated with
monogenic diseases (MD-PG). Accordingly, mutations in MD-PG
genes seem to ‘‘diverge’’ disturbances more efficiently by protein-
protein interactions that determine a pathophenotypic and
functional relationship between genes. This result suggests that
these genes co-participate in different variants of a given disease
and there are functional co-dependencies among them. Thus, we
proceeded to assess whether the specificity of the pathophenotypic
similarity between genes depends on their type of biological
interaction. For that reason, we performed a validation analysis
through receiver operating characteristic (ROC) curves to prove
the signal in pathophenotypic similarities produced by each
biomolecular interactome in PSGN (Figure 7). PIN and MGN
showed higher average areas under the ROC curves (AUC values
of 0.77 and 0.76, respectively) than functional interactions with an
average AUC of 0.66 (Figure 7). Both biochemical interactomes
have a strong signal, as depicted by ROC far from the straight line
representing randomness (Figure 7). This observation reinforces
the idea that strong synergies occur between genes involved in
biochemical interactions. The functional network (Figure 7) also
shows a signal clearly departed from the straight line representing
randomness that is consistent with previous works [27]. However,
one should be aware that there is always some degree of
nonspecific relationships that can introduce noise in this kind of
analysis.
Merging modular components of MSUD using
pathophenotypic similarity. We analyzed a metabolic disor-
der named as maple syrup urine disease (MSUD, MIM 248600).
MSUD is a genetic disease grouped into aminoacidurias and
caused by a decreased activity of the branched-chain alpha-
ketoacid dehydrogenase (BCKD) complex. It catalyzes the first
steps for the degradation of branched-chain amino acids (valine,
leucine and isoleucine). This enzymatic complex has three subunits
(E1, E2, and E3) encoded by four different genes BCKDHA-E1A
(Entrez GeneID 593), BCKDHB-E1B (Entrez GeneID 594),
DBT-E2 (Entrez GeneID 1629), and DLD-E3 (Entrez GeneID
1738). This inborn error of metabolism is genetically and
phenotypically well characterized [47]. The classical clinical
features associated with MSDU are: maple syrup odor in cerumen
(hours after birth), increased levels of branched -chain amino-acids
(valine, leucine and isoleucine), ketonuria, signs of deepening
encephalopathy, coma and central respiratory failure. We
retrieved a map of all pathophenotypes annotated for MSUD-
causing genes (Figure S3). From PSGN, we retrieved all gene pairs
including at least one of the MSUD causing genes, but before we
removed a dense cluster linked to DLD due to Leigh syndrome
(Figure 8 A). Some of the resulting genes also present direct or
non-direct metabolic flux correlations with BCKDHA, BCKDHB,
DBT or DLD (Figure 8 A) and most of them take part in different
reactions of the valine, leucine and isoleucine degradation pathway
Table 6. Counts of nodes and edges in the comparison of PSGN and biomolecular interactomes.
PIN MGN FSGN
Symbol Description Nodes Edges Nodes Edges Nodes Edges
R Reference (PSGN) 1233 15550 131 321 1381 17233
Q Query (biomolecular interactome) 903 1779 154 1060 1376 30318
QvR Union 1240 16907 158 1257 1387 45078
QˆR Intersection 896 422 127 124 1370 2473
Q!R Query not reference 7 1357 27 936 6 27845
R!Q Reference not query 337 15128 4 197 11 14760
All calculations were performed using NeAT [28]. The query is PSGN and used reference corresponds to each biomolecular interactomes.
doi:10.1371/journal.pone.0056653.t006
Table 7. Significance of the number of edges at the resulting intersection in the network analysis comparison.
PIN MGN FSGN
Symbol Description Formula Network Random Network Random Network Random
N Nodes in the union – 1240 1238 158 158 1387 1387
M Max number of edges in the union M=N*(N21)/2 768180 765703 12403 12403 961191 961191
E(QˆR) Expected edges in the intersection E(QˆR) =Q*R/M 36.01 27.96 27.43 24.33 543.57 196.95
QˆR Observed edges in the intersection – 422 35 124 17 2473 194
Q (%) Percentage of query edges perc_Q=100*QˆR/Q 23.72 2.54 11.70 1.81 8.16 1.77
R (%) Percentage of reference edges perc_R = 100*QˆR/R 2.71 0.23 38.63 5.30 14.35 1.13
Jac_sim Jaccard coefficient of similarity Jac_sim= QˆR/(QvR) 0.0250 0.0021 0.0986 0.0137 0.0549 0.0069
P value P-value of the intersection Pval = P(X.= QˆR) 4.0E2308 1.1E201 2.7E251 9.6E201 1E2321a 5.9E-01
All calculations were performed using NeAT [28]. The query is PSGN and used reference corresponds to each biomolecular interactomes. In bold, those significant p-
values.
aThe limit of precision for the hypergeometric test.
doi:10.1371/journal.pone.0056653.t007
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(Figure 8 B). This evidence that integrating functional co-
dependencies and pathophenotypic similarities merge apparently
non-related genes into a module of the molecular pathobiology.
Furthermore, we can breakdown the module relationships to map
shared pathophenotypes between genes (Figure 8 C). For instance,
IVD and ACADM are genes included in MD-MG subsets for both
HDN and ODN. However, in this sub-network (Figure 8 A) we
detect that they are sharing pathophenotypes with MSUD genes
(Figure 8 C). It is possible to identify the set of the most specific
pathophenotypes for MSUD, elevated plasma branched chain
aminoacids or hallucinations. In addition, PCCA and PCCB
appear with similar clinical biochemistry parameters highly
correlated with MSUD, such as high levels of lactic acid and
ketone bodies (Figure 8 C). In contrast, other pathophenotypes
point to disorders at a systemic or pathophysiological level, such as
cerebral edema, pancreatitis, lethargy and coma (Figure 8 C).
Nevertheless, these genes are grouped in the same biological
context (Figure 8 B) and, it is important to remark, that all of them
are in the mitochondrial matrix.
This metabolic syndrome illustrates the potentials of PSGN.
This network provides novel pathological similarities between
genes and outlines the pathobiology and functional context of
disease-causing genes using metabolic interactions.
Overlapped physical and pathophenotypic interactions
disregarded in unipartite projections. Finally, given the
relevance of the physical interactions, we carried out a manual
exploration of the intersection between PIN and PSGN. This is to
remove all those gene-to-gene edges in both HDGN and ODGN
from the resulting intersection. This resulted in the selection of all
the disregarded relationships between genes in unipartite projec-
tions of diseasomes that are phenotypically and physically related
(Figure 9 and Table S10). Therefore, tuning the balance between
the ‘‘noise’’ and the confidence of interactions may improve the
predictive power of new disease-related genes using network
medicine approaches based on pathophenotypic term.
Conclusions
Current studies in medical genetics are mainly centered in
establishing associations among diseases and genetic variations for
Figure 7. Receiver operative characteristic (ROC) curve performance by biomolecular interactions of pathophenotypic similarities.
Physical interactions (dashed blue line), metabolic flux correlations (dashed green line), functional interactions (red continuous line) and an integrated
interactome generated by the sum of all other interactomes (black continuous line). ROC curves were computed to assess the signal of
pathophenotypic similarities for biological interactions. True positives (TP) were those interactions that where found in the intersection between
PSGN and each biomolecular interactome (PIN, MGN and FSGN). The dataset of false positives (FP) was calculated from intersected gene pairs
between PSGN and randomizations of each biomolecular interactome. We obtained severals different FP datasets to calculate the average area under
the curve (AUC), it was 0.77 for PIN, 0.76 for MGN, 0.66 for FSGN and 0.68 for the integrated interactome. Only biochemical interactomes show
significantly different AUCs to that of the integrated interactome (average p-values of 2.2E26 and 4.1E22 for PIN and MGN respectively).
doi:10.1371/journal.pone.0056653.g007
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personalized medicine. Many of these genetic variations are
located in intragenic regions of DNA and they constitute the basic
data to build disease-causing gene networks [10,11]. These
networks are useful to find new genetic interactions between
diseases, as well as to predict the influence of gene functions in
existing pathologies [48–50]. In the present work, we have
classified the different patterns of gene-disease associations in four
subsets according to two different criteria (MD-MG, MD-PG, PD-
MG, PD-PG, as depicted in Figure 1C). This is in contrast to
previously published works in which only one criterion was used,
either specific and shared genes by diseases [30] or monogenic or
polygenic disease-causing genes [31,51]. Our findings indicate that
the inferred associations are insufficient to describe properly both
interactions among diseases and among genes. This effect can be
easily observed when analyzing bipartite graphs composed of
gene-to-disease edges. In these networks, more than 30% of the
genes participate in ‘‘bi-univocal’’ relationships (that is, genes
associated exclusively with a single disease). This specificity can be
useful for diagnostics, but it makes it more difficult to establish
groups or to identify interactions among diseases. On the other
hand, our results have also uncovered an enrichment of metabolic
genes in bi-univocal subsets, as well as an enrichment of essential
genes in pleiotropic subsets. The lack of cellular and molecular
phenotyping platforms constrains the possibility to detect shared
features among pathologies. Consequently, this reduces the
possibilities of generating new knowledge on the molecular bases
of the pathophenotypic profiles, to distinguish classes and
subclasses of a given disease more precisely [7,11,26]. However,
medical semantics remains the standard tool to establish the sets of
observed clinical features associated with pathologies. In the case
of diseases with predominantly genetic origins, pathophenotypes
are usually very conserved among patients. We have shown that
pathophenotypic similarity gene networks can be a great resource
to uncover the molecular mechanisms involved in the responses of
organisms to genetic disturbances. For instance, it shows to be
useful to merge biomolecular components involved in a same
pathological process like MSUD.
In the future, network integration and standardization of
molecular and cellular phenotypes could improve the understand-
ing of the evolutionary mechanisms involved in pathological
processes. Further experimental and analytical efforts in this
direction are warranted.
Figure 8. Maple syrup urine disease pathological and metabolic interactions. In red genes associated with MSUD and in blue
pathophenotypic similar genes. (A) Pathophenotypic similarity gene sub-network for MSUD causing genes. It can be noteworthy that there are no
inferred relationships between MSUD genes and the rest. (B) Map of branched-chain amino acid degradation pathway from. This map has been
extracted from the Kyoto Encyclopedia of Genes and Genomes (KEGG, hsa:00280) developed by Kanehisa Laboratories. Enzymes encoded by human
genes are in green. (C) Pathophenotypes shared between genes in the same metabolic module.
doi:10.1371/journal.pone.0056653.g008
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Supporting Information
Figure S1 Schematic representation of the workflow of
essential steps followed in this study: building network
processes, optimal statistical threshold selection, net-
work comparisons, topological analysis and ROC curve
construction.
(PDF)
Figure 9. Physical interactions between genes with similar phenotypic lost in the current networks of diseases. This figure is the result
of the difference of the resulting intersection between PSGN and PIN after removing those interactions present in HDGN and ODGN. Those genes
that are MD-MG in HDN and ODN have been coloured in orangeThese genes indicate that they present underlying pathophenotypical relationships
with other genes that had been disregarded by the inference of shared disease genes.
doi:10.1371/journal.pone.0056653.g009
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Figure S2 Spearman correlation between the number of
pathophenotypes per gene and the average pathopheno-
typic similarity per gene for PSGN genes.
(PDF)
Figure S3 Graph of the pathophenotypes annotated to
maple syrup urine syndrome. Parental nodes are close
to the root in the human phenotype ontology and,
therefore, with lower specificity. In contrast, child
nodes are the most informative and specific pathological
phenotypes.
(PDF)
Table S1 Bipartite and unipartite projections of the
updated version of the human diseases network.
(XLS)
Table S2 Bipartite and unipartite projections of the
updated version of the orphan disease network.
(XLS)
Table S3 Different gene subsets in the human diseases
network following proposed classification.
(XLS)
Table S4 Different gene subsets in the orphan diseases
network following proposed classification.
(XLS)
Table S5 Different biomolecular interactomes based on
physical, metabolic and functional interactions.
(XLS)
Table S6 Biomolecular interactome and PSGN sub-
networks after nodal intersections.
(XLS)
Table S7 Pathophenotypic similarity gene network.
(XLS)
Table S8 Spearman correlations between gene degrees
in PSGN and HDGN/ODGN.
(PDF)
Table S9 Spearman correlation between gene degrees
in PSGN and biomolecular interactomes.
(PDF)
Table S10 Network intersection between PSGN and PIN
removing inferred gene-to-gene associations.
(XLS)
Methods S1
(PDF)
Acknowledgments
The authors thank J.R. Perkins and I. Morilla for useful comments and
suggestions.
Author Contributions
Conceived and designed the experiments: ARP RRL. Performed the
experiments: ARP RRL. Analyzed the data: ARP RRL JAGR FSJ MAM.
Contributed reagents/materials/analysis tools: ARP RRL JAGR FSJ
MAM. Wrote the paper: ARP RRL FSJ MAM.
References
1. Benfey PN, Mitchell-Olds T (2008) From Genotype to Phenotype: Systems
Biology Meets Natural Variation. Science 320 : 495–497.
2. Hidalgo CA, Blumm N, Baraba´si A-L, Christakis NA (2009) A Dynamic
Network Approach for the Study of Human Phenotypes. PLoS Comput Biol 5:
e1000353.
3. Baraba´si A-L, Oltvai ZN (2004) Network biology: understanding the cell’s
functional organization. Nat Rev Genet 5: 101–113.
4. Albert R, Baraba´si A-L (2002) Statistical mechanics of complex networks. Rev
Mod Phys 74: 47–97.
5. Zhu X, Gerstein M, Snyder M (2007) Getting connected: analysis and principles
of biological networks. Genes Dev 21: 1010–1024.
6. Albert R (2005) Scale-free networks in cell biology. J Cell Sci 118: 4947–4957.
7. Baraba´si A-L, Gulbahce N, Loscalzo J (2011) Network medicine: a network-
based approach to human disease. Nat Rev Genet 12: 56–68.
8. Amberger J, Bocchini CA, Scott AF, Hamosh A (2009) McKusick’s Online
Mendelian Inheritance in Man (OMIMH). Nucleic Acids Research 37 : D793–
D796.
9. Ayme´ S (2003) Orphanet, an information site on rare diseases. Soins: 46–47.
10. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human
disease network. Proc Natl Acad Sci U S A 104 : 8685–8690.
11. Zhang M, Zhu C, Jacomy A, Lu LJ, Jegga AG (2011) The orphan disease
networks. Am J Hum Genet 88: 755–766.
12. Vidal M, Cusick ME, Baraba´si A-L (2011) Interactome Networks and Human
Disease. Cell 144: 986–998.
13. Park J, Lee D-S, Christakis NA, Barabasi A-L (2009) The impact of cellular
networks on disease comorbidity. Mol Syst Biol 5.
14. Ideker T, Sharan R (2008) Protein networks in disease. Genome Research 18 :
644–652.
15. Lee D-S, Park J, Kay KA, Christakis NA, Oltvai ZN, et al. (2008) The
implications of human metabolic network topology for disease comorbidity. Proc
Natl Acad Sci U S A 105 : 9880–9885.
16. Guan Y, Myers CL, Lu R, Lemischka IR, Bult CJ, et al. (2008) A Genomewide
Functional Network for the Laboratory Mouse. PLoS Comput Biol 4: e1000165.
17. Linghu B, Snitkin E, Hu Z, Xia Y, DeLisi C (2009) Genome-wide prioritization
of disease genes and identification of disease-disease associations from an
integrated human functional linkage network. Genome Biol 10: R91.
18. Auffray C, Chen Z, Hood L (2009) Systems medicine: the future of medical
genomics and healthcare. Genome Med 1: 2.
19. Loscalzo J, Barabasi A-L (2011) Systems biology and the future of medicine.
Wiley Interdiscip Rev Syst Biol Med 3: 619–627.
20. Robinson PN (2012) Deep phenotyping for precision medicine. Hum Mutat 33:
777–780.
21. Robinson PN, Ko¨hler S, Bauer S, Seelow D, Horn D, et al. (2008) The Human
Phenotype Ontology: A Tool for Annotating and Analyzing Human Hereditary
Disease. Am J Hum Genet 83: 610–615.
22. Osborne J, Flatow J, Holko M, Lin S, Kibbe W, et al. (2009) Annotating the
human genome with Disease Ontology. BMC Genomics 10: S6.
23. Espinosa O, Hancock JM (2011) A Gene-Phenotype Network for the Laboratory
Mouse and Its Implications for Systematic Phenotyping. PLoS ONE 6: e19693.
24. Robinson PN, Mundlos S (2010) The Human Phenotype Ontology. Clin Genet
77: 525–534.
25. Ko¨hler S, Schulz MH, Krawitz P, Bauer S, Do¨lken S, et al. (2009) Clinical
Diagnostics in Human Genetics with Semantic Similarity Searches in
Ontologies. Am J Hum Genet 85: 457–464.
26. Oti M, Huynen MA, Brunner HG (2009) The Biological Coherence of Human
Phenome Databases. Am J Hum Genet 85: 801–808.
27. Zhang S, Chang Z, Li Z, DuanMu H, Li Z, et al. (2012) Calculating phenotypic
similarity between genes using hierarchical structure data based on semantic
similarity. Gene 497: 58–65.
28. Brohee S, Faust K, Lima-Mendez G, Vanderstocken G, Van Helden J (2008)
Network Analysis Tools: from biological networks to clusters and pathways. Nat
Protocols 3: 1616–1629.
29. Bossi A, Lehner B (2009) Tissue specificity and the human protein interaction
network. Mol Syst Biol 5: 260.
30. Chavali S, Barrenas F, Kanduri K, Benson M (2010) Network properties of
human disease genes with pleiotropic effects. BMC Syst Biol 4: 78.
31. Cai JJ, Borenstein E, Petrov DA (2010) Broker Genes in Human Disease.
Genome Biol Evol 2 : 815–825.
32. Lee D-S (2010) Interconnectivity of human cellular metabolism and disease
prevalence. J Stat Mech 12015: P12015.
33. Montan˜ez R, Medina MA, Sole´ R V, Rodrı´guez-Caso C (2010) When
metabolism meets topology: Reconciling metabolite and reaction networks.
Bioessays 32: 246–256.
34. Veeramani B, Bader JS (2009) Metabolic Flux Correlations, Genetic
Interactions, and Disease. J Comput Biol 16: 291–302.
35. Rolfsson O, Palsson B, Thiele I (2011) The human metabolic reconstruction
Recon 1 directs hypotheses of novel human metabolic functions. BMC Syst Biol
5: 155.
36. Resnik P (1995) Using Information Content to Evaluate Semantic Similarity in a
Taxonomy. IJCAI. 448–453.
37. Mistry M, Pavlidis P (2008) Gene Ontology term overlap as a measure of gene
functional similarity. BMC Bioinformatics 9: 327.
38. Xu T, Du L, Zhou Y (2008) Evaluation of GO-based functional similarity
measures using S. cerevisiae protein interaction and expression profile data.
BMC Bioinformatics 9: 472.
Using Pathological Phenotypes for Human Diseasomes
PLOS ONE | www.plosone.org 18 February 2013 | Volume 8 | Issue 2 | e56653
Page 96 of 210
39. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T (2011) Cytoscape 2.8:
new features for data integration and network visualization. Bioinformatics 27 :
431–432.
40. Brohe´e S (2012) Using the NeAT Toolbox to Compare Networks to Networks,
Clusters to Clusters, and Network to Clusters. Methods in molecular biology
(Clifton, N.J.). Springer New York, Vol. 804. 327–342.
41. Fawcett T (2006) An introduction to ROC analysis. Pattern Recognit Lett 27:
861–874.
42. Van Driel MA, Bruggeman J, Vriend G, Brunner HG, Leunissen JAM (2006) A
text-mining analysis of the human phenome. Eur J Hum Genet 14: 535–542.
43. Xie M, Hwang T, Kuang R (2012) Reconstructing Disease Phenome-genome
Association by Bi-Random Walk. Bioinformatics 1: 1–8.
44. Bult CJ, Eppig JT, Kadin JA, Richardson JE, Blake JA (2008) The Mouse
Genome Database (MGD): mouse biology and model systems. Nucleic Acids
Res 36: D724–8.
45. Wagner GP, Zhang J (2011) The pleiotropic structure of the genotype–
phenotype map: the evolvability of complex organisms. Nat Rev Genet 12: 204–
213.
46. Hill WG, Zhang X-S (2012) On the Pleiotropic Structure of the Genotype–
phenotype Map and the Evolvability of Complex Organisms. Genetics.
47. Nellis MM, Danner DJ (2001) Gene preference in maple syrup urine disease.
Am J Hum Genet 68: 232–237.
48. Wheelock CE, Wheelock AM, Kawashima S, Diez D, Kanehisa M, et al. (2009)
Systems biology approaches and pathway tools for investigating cardiovascular
disease. Mol Biosyst 5: 588–602.
49. Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, et al. (2009)
Pathway and network-based analysis of genome-wide association studies in
multiple sclerosis. Hum Mol Genet 18: 2078–2090.
50. Cerami E, Demir E, Schultz N, Taylor BS, Sander C (2010) Automated
Network Analysis Identifies Core Pathways in Glioblastoma. PLoS ONE 5:
e8918.
51. Feldman I, Rzhetsky A, Vitkup D (2008) Network properties of genes harboring
inherited disease mutations. Proc Natl Acad Sci U S A 105 : 4323–4328.
Using Pathological Phenotypes for Human Diseasomes
PLOS ONE | www.plosone.org 19 February 2013 | Volume 8 | Issue 2 | e56653
Page 97 of 210
!CHAPTER 3. PUBLICATION 3  
 
 
 
 
 
 
 
 
Supplementary Material for: 
 
Global Analysis of the Human Pathophenotypic 
Similarity Gene Network Merges Disease Module 
Components 
 
Supplementary material INCLUDED in this Thesis: 
 
Methods S1. 
doi:10.1371/journal.pone.0056653.s014 
 
Figure S1. 
Schematic representation of the workflow of essential steps followed in this study: 
building network processes, optimal statistical threshold selection, network comparisons, 
topological analysis and ROC curve construction. 
doi:10.1371/journal.pone.0056653.s001 
 
Figure S2. 
Spearman correlation between the number of pathophenotypes per gene and the 
average pathophenotypic similarity per gene for PSGN genes. 
doi:10.1371/journal.pone.0056653.s002 
 
Figure S3. 
Graph of the pathophenotypes annotated to maple syrup urine syndrome. Parental 
nodes are close to the root in the human phenotype ontology and, therefore, with lower 
specificity. In contrast, child nodes are the most informative and specific pathological 
phenotypes. 
doi:10.1371/journal.pone.0056653.s003 
 
Table S8. 
Spearman correlations between gene degrees in PSGN and HDGN/ODGN. 
doi:10.1371/journal.pone.0056653.s011 
 
Table S9. 
Spearman correlation between gene degrees in PSGN and biomolecular interactomes. 
doi:10.1371/journal.pone.0056653.s012 
 
 
Page 99 of 210
!This supplementary material is NOT INCLUDED in this Thesis but it is 
available online: 
 
Table S1. 
Bipartite and unipartite projections of the updated version of the human diseases 
network. 
doi:10.1371/journal.pone.0056653.s004 
 
Table S2. 
Bipartite and unipartite projections of the updated version of the orphan disease 
network. 
doi:10.1371/journal.pone.0056653.s005 
 
Table S3. 
Different gene subsets in the human diseases network following proposed classification. 
doi:10.1371/journal.pone.0056653.s006 
 
Table S4. 
Different gene subsets in the orphan diseases network following proposed classification. 
doi:10.1371/journal.pone.0056653.s007 
 
Table S5. 
Different biomolecular interactomes based on physical, metabolic and functional 
interactions. 
doi:10.1371/journal.pone.0056653.s008 
 
Table S6. 
Biomolecular interactome and PSGN sub-networks after nodal intersections. 
doi:10.1371/journal.pone.0056653.s009 
 
Table S7. 
Pathophenotypic similarity gene network. 
doi:10.1371/journal.pone.0056653.s010 
 
Table S10. 
Network intersection between PSGN and PIN removing inferred gene-to-gene 
associations. 
doi:10.1371/journal.pone.0056653.s013  
Page 100 of 210
In
te
rs
ec
te
d 
ge
ne
 p
ai
rs
 
TR
U
E 
PO
SI
TI
VE
S 
(T
P)
 
In
te
rs
ec
tio
n 
of
 g
en
e 
pa
irs
 (e
dg
es
) 
In
te
ra
ct
om
es
 
P
S
G
N
 
Pa
th
op
he
no
ty
pi
c 
si
m
ila
rit
y 
sc
or
es
 b
et
w
ee
n 
ge
ne
s 
S
em
an
tic
 s
im
ila
rit
y 
m
ea
su
re
 
(K
öh
le
r e
t a
l. 
20
09
) 
H
PO
  
on
to
lo
gy
 
H
PO
 g
en
e 
 
an
no
ta
tio
ns
 
F
S
G
N
 
91
57
%n
od
es
%
49
69
73
%e
dg
es
%
Fi
lte
rin
g 
ou
t l
ow
 s
co
re
 g
en
e 
pa
irs
 (u
nd
er
 9
9.
5t
h  p
er
ce
nt
ile
) 
Fu
nc
tio
na
l s
im
ila
rit
y 
sc
or
es
 
be
tw
ee
n 
ge
ne
s 
S
em
an
tic
 s
im
ila
rit
y 
m
ea
su
re
 
(R
es
ni
k 
et
 a
l. 
19
95
) 
G
O
 B
P 
on
to
lo
gy
 
G
O
 g
en
e 
an
no
ta
tio
ns
 
M
G
N
  
53
5%
no
de
s%
98
12
%e
dg
es
%
Fi
lte
rin
g 
ou
t l
ow
 fl
ux
 c
or
re
la
tio
n 
ge
ne
 p
ai
rs
 (e
qu
al
 o
r u
nd
er
 0
.1
) 
Fi
lte
rin
g 
ou
t “
m
et
sc
or
e”
 g
en
e 
pa
irs
 e
qu
al
 to
 z
er
o 
Fl
ux
 B
al
an
ce
 A
na
ly
si
s 
of
 H
um
an
 
M
et
ab
ol
ic
 N
et
w
or
k 
R
ec
on
 1
 
(V
ee
ra
m
an
i e
t a
l. 
20
09
)  
P
IN
 
95
80
%n
od
es
%
74
65
7%
ed
ge
s%
M
ap
pi
ng
 E
N
S
E
M
B
L 
G
en
e 
ID
 to
 
E
nt
re
z 
G
en
eI
D
 
A
t l
ea
st
 o
ne
 e
xp
er
im
en
ta
l 
ev
id
en
ce
 
C
R
G
 H
um
an
 In
te
ra
ct
om
e 
(B
os
si
 e
t a
l. 
20
09
) 
1.
 
M
an
n-
W
hi
tn
ey
 te
st
 fo
r d
eg
re
e 
di
st
rib
ut
io
ns
 o
f g
en
e 
su
bs
et
s 
 
2.
 
S
pe
ar
m
an
's
 ra
nk
 c
or
re
la
tio
n 
te
st
 o
f g
en
e 
de
gr
ee
s 
 
B
IO
M
O
LE
C
U
LA
R
 IN
TE
R
A
C
TO
M
ES
 
PS
G
N
 
TO
PO
LO
G
YC
A
L 
A
N
A
LY
SI
S 
(n
od
e 
de
gr
ee
) Se
le
ct
io
n 
of
 th
e 
cu
t-o
ff 
at
 th
e 
98
th
 p
er
ce
nt
ile
 
O
pt
im
al
 s
ta
tis
tic
al
 th
re
sh
ol
d 
of
 s
im
ila
rit
y 
sc
or
e 
(R
O
C
 c
ur
ve
) 
Tr
ue
 p
os
iti
ve
s:
 
in
te
rs
ec
te
d 
Fa
ls
e 
po
si
tiv
es
: 
N
on
-in
te
rs
ec
te
d 
Yo
ud
en
´s
 in
de
x 
In
te
rs
ec
tio
n 
of
 g
en
e 
pa
irs
 (e
dg
es
) 
A
ll 
pa
th
op
he
no
ty
pi
ca
lly
 s
im
ila
r g
en
e 
pa
irs
 
U
ni
on
 o
f u
ni
pa
rti
te
 p
ro
je
ct
io
ns
 
U
N
IO
N
 O
F 
U
N
IP
A
R
TI
TE
 P
R
O
JE
C
TI
O
N
S 
H
D
G
N
 
O
D
G
N
 
P
S
G
N
 
17
05
%n
od
es
%
26
19
7%
ed
ge
s%
Fi
lte
rin
g 
ou
t l
ow
 s
co
re
 g
en
e 
pa
irs
 (u
nd
er
 9
8t
h  p
er
ce
nt
ile
) 
0e
+0
0
2e
+0
4
4e
+0
4
6e
+0
4
8e
+0
4
1e
+0
5
050010001500
G
en
es
 v
s 
ge
ne
 p
ai
rs
G
en
e 
pa
irs
Genes
95
th
98
th
99
th
R
ep
ea
tin
g 
un
til
 th
e 
nu
m
be
r o
f F
P 
eq
ua
ls
 T
P 
 
In
te
rs
ec
te
d 
ge
ne
 p
ai
rs
 
FA
LS
E 
PO
SI
TI
VE
S 
(F
P)
 
In
te
rs
ec
tio
n 
of
 g
en
e 
pa
irs
 (e
dg
es
) 
R
an
do
m
 in
te
ra
ct
om
es
 
P
S
G
N
 
B
io
m
ol
ec
ul
ar
 s
ub
-n
et
w
or
ks
  
(b
y 
sh
ar
ed
 g
en
es
 w
ith
 P
SG
N
) 
PS
G
N
 s
ub
-n
et
w
or
ks
 
(b
y 
sh
ar
ed
 g
en
es
 w
ith
 in
te
ra
ct
om
es
) 
R
an
do
m
iz
at
io
ns
 
(c
on
se
rv
in
g 
de
gr
ee
 d
is
tr
ib
ut
io
n)
 
In
te
rs
ec
tio
n 
of
 g
en
es
 (n
od
es
) 
Si
gn
ifi
ca
nc
e 
of
 th
e 
si
m
ila
rit
y 
(b
as
ed
 o
n 
re
su
lti
ng
 in
te
rs
ec
tio
ns
) 
Ja
cc
ar
d 
co
ef
fic
ie
nt
 
H
yp
er
ge
om
et
ric
 te
st
 
N
ET
W
O
R
K
 A
N
A
LY
SI
S 
C
O
M
PA
R
IS
O
N
 
B
et
w
ee
n 
in
te
ra
ct
om
es
 a
nd
 P
SG
N
 s
ub
ne
tw
or
ks
 
B
et
w
ee
n 
ra
nd
om
 in
te
ra
ct
om
es
 a
nd
 P
SG
N
 
su
bn
et
w
or
ks
 
Te
st
 b
et
w
ee
n 
R
O
C
 c
ur
ve
s 
of
 e
ac
h 
in
te
ra
ct
om
e 
an
d 
R
O
C
 
cu
rv
es
 o
f t
he
 in
te
gr
at
ed
 in
te
ra
ct
om
e 
(u
ni
on
 o
f t
hr
ee
 
in
te
ra
ct
om
es
)  
Av
er
ag
e 
A
re
a 
U
nd
er
 d
e 
C
ur
ve
 (A
U
C
) 
PE
R
FO
R
M
A
N
C
E 
VA
LI
D
AT
IO
N
 A
N
D
 R
O
C
 C
A
LC
U
LA
TI
O
N
S 
R
O
C
 c
ur
ve
 o
f s
im
ila
rit
y 
sc
or
es
Fa
ls
e 
po
si
tiv
e 
ra
te
True positive rate
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.00.20.40.60.81.0
0.021.382.734.095.456.81
1.
39
 (0
.0
7,
 0
.8
)
1.
 C
O
N
ST
R
U
C
TI
O
N
 O
F 
IN
TE
R
A
C
TO
M
ES
 A
N
D
 S
EM
A
N
TI
C
 S
IM
IL
A
R
IT
Y 
B
A
SE
D
 N
ET
W
O
R
K
S 
 
2.
 S
TA
TI
ST
IC
A
L 
TH
R
ES
H
O
LD
 A
N
D
 C
U
T-
O
FF
 S
EL
EC
TI
O
N
 
3.
 N
ET
W
O
R
K
 A
N
A
LY
SI
S 
   
 C
O
M
PA
R
IS
O
N
 
4.
 C
A
LC
U
LA
TI
O
N
 O
F 
R
O
C
 C
U
R
VE
S 
B
Y 
IN
TE
R
SE
C
TE
D
 
   
 G
EN
E 
PA
IR
S 
Page 101 of 210
0 20 40 60 80 100
0
1
2
3
4
5
Number of pathophenotypes (HPO terms) per gene
M
ea
n 
va
lu
e 
of
 p
at
op
he
no
ty
pi
c 
si
m
ila
rit
y 
pe
r g
en
e
Spearman correlation test (rho = -0.25 , P-value  1.8e-26 )
Page 102 of 210
Page 103 of 210
Supplementary methods and discussion section for 
 
“Global Analysis of the Human Pathophenotypic Similarity 
Gene Network Merges Disease Module Components” 
 
 
 
Armando Reyes-Palomares1,2, Rocio Rodríguez-López1,2, Juan AG Ranea1,2, Francisca 
Sánchez Jiménez1,2, Miguel Angel Medina1,2 
 
 
 
 
1Department of Molecular Biology and Biochemistry, Faculty of Sciences, University 
of Málaga, E-29071 Málaga, Spain 
2CIBER de Enfermedades Raras (CIBERER), E-29071 Málaga, Spain 
 
 
 
 
 
 
*To whom correspondence should be addressed. 
Email: medina@uma.es 
 
 
 
 
!
!
Page 104 of 210
 Procedures to select the similarity score cutoff 
1. Introduction 
A systematic methodology to identify significant semantic similarities (similarity 
scores) has not been yet established. We therefore propose a few systematic steps to set 
aside what can be considered as significant similarity scores, in agreement to the current 
genetic association and ontological structure knowledge. The semantic similarity 
proposed by Resnik computes as informative is each term [1]. The information content 
(also known by IC) of an ontological term depends on its relative frequency, the number 
of annotations of a term respect to the whole set of annotations (corpus). It means that a 
high of informativeness indicates more specificity and fewer annotations. Hence, the 
similarity between terms will be assessed calculating the IC of the most informative 
common ancestor (MICA) derived from the ontological structure. 
We have calculated all similarity scores (pathophenotypic similarities) between 
annotated genes in the Human Phenotype Ontology (HPO) [2]. For this, we used an IC-
based measure [3] resulting in 1309578 similarity scores between 1812 genes, 
excluding zero scores. In this study, genes are annotated with a set of HPO terms 
describing the pathological processes related to them by genetic association studies. 
Accordingly, the computed scores are themselves probabilistic estimations of the 
pathophenotypic similarity between genes respect to the total number of pathological 
phenotypes (HPO terms) comprehended in the study.  
In this case, the percentile can be considered as a suitable parameter to decide a level of 
significance for all ranked scores. However, it is assumed that most of the computed 
pathophenotypic relationships between genes are non-informative although they are 
statistically recognizable by their similarity score. Furthermore, HPO is a controlled 
vocabulary that has been manually revised and structured as a direct acyclic graph 
(DAG) [4]. Consequently, the similarity scores depends on the current knowledge 
represented in HPO, where some relationships can be missing and general domains 
cluster many terms. It means that noise could be present in any computed similarity 
score using biomedical ontologies [5], so the identification of an optimal statistical 
threshold remains as the greatest difficulty. This is to set the limit of similarity score 
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from which gene-gene relationships are significantly informative. Therefore, we have 
two main purposes to identify this optimal statistical threshold and, once it has been 
assessed, to select the most appropriate cutoff of similarity score.  
2. Procedure 
We started by analyzing the properties of all the computed pathophenotypic similarities. 
The similarity score distribution reveals that lower values are clearly more frequent 
(more probable) than higher ones (Figure 1). Indeed, it is in line with the information 
content computed by the semantic similarity measurement applied for this work [6], 
which also uses the relative frequency. 
 
Figure 1. Histogram of gene pairs per similarity score. The number of gene pairs for each 
similarity score after to remove zero scores. It can be note that a high frequency for bars located the 
region of lower similarity scores. 
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Figure 1 represents the number of gene pairs counted for each score. In some cases, 
similarity scores reach more than 10000 pairs of genes and they are located along the 
region of smaller values. This may be due to the fact that low similarity scores have 
been computed by HPO terms close to the root of the ontology conforming general 
domains (clusters) of non-specific pathophenotypic similarities between genes. 
Therefore, these domains lack of significant information to become constituent elements 
of the pathophenotypic gene similarity network (PSGN). These clustering effects can be 
observed by analyzing the number of resulting genes at different cutoffs among the 
whole range of similarity scores. Thus we used 1000 different cutoffs to study in details 
variations on this distribution. For instance, it could be appreciated that the number of 
participating genes decreases as the similarity score cut-off increases (Figure 2); what 
indicates that genes are not taken into account if they are not participating in any 
relationship over the threshold.  
 
Figure 2. Number of genes counted at each similarity score cutoffs. One thousand equidistant 
cutoffs were established along the whole range of similarity scores. Subsequently, gene pairs with a score 
equal or greater than the used cutoff were selected and resulting genes were counted. 
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As can be noted, the clustering effects are more evident for higher similarity scores 
where little variations lead to introduce strong differences in the number of genes. In 
contrast, the number of genes is well conserved when using low similarity scores as 
cutoffs. However, along this flat area, we observe abrupt shifts in the number of genes, 
whose can be due to discard scores associated with HPO terms grouping many genes 
(group of genes sharing HPO annotations). The number of genes is stable but the gene 
pairs decreased exponentially until it reaches scores higher than approximately 1.5 
(Figure 3). 
 
Figure 3. Number of gene pairs for similarity scores cutoff. One thousand equidistant cutoffs 
were established along the whole range of similarity scores. All gene pairs with a score equal or greater 
than the used cutoff were selected. Three types of areas can be approximately defined: vertical asymptote 
(approx. from 0 to 1.0 cutoffs), turning point of the curvature (approx. from 1.0 to 2.0 cutoffs) and 
horizontal asymptote (approx. from 2.0 to 1.0 cutoffs). 
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Figure 3 represents a curve with three different zones: a vertical asymptote, a curvature 
and a horizontal asymptote. The vertical asymptote represents a clear lineal dependency 
between the used cutoff and the number of gene pairs. Then, many gene-gene 
relationships are affected by minor variations in the similarity score during the analysis. 
This result can be partially explained by hierarchical dependencies between HPO terms 
in the ontology and suggests the exponential growth of nonspecific similarities as the 
score drops. On the other hand, the horizontal asymptote seems to indicate that the 
number of gene pairs is conserved when the cutoff has reached a certain score. But what 
really happens is that the specificity increases considerably with higher values of 
semantic similarity, what means that genes are sharply clustered. Hence, the curvature 
represents the threshold to distinguish from low to high signal-to-noise ratio, in the 
vertical and horizontal asymptote, respectively (Figure 3).  
 
3. Results for threshold and cutoff selection 
Different approaches were used to assess the biological relevance of this threshold in 
order to maximize noise-reduction and specificity. Subsequently, this optimal threshold 
should be the reference value from which to set the most appropriated cut-off to build 
the PSGN. 
First off all, we performance a binary classifier system and illustrate it in a receiver 
operating characteristic (ROC) curve. This binary system was built from gene pairs 
showing pathophenotypic similarity (1309578 gene pairs) that were present or absent in 
the union of both unipartite projections (HDGN and ODGN). We joined all inferred 
interactions from HDGN and ODGN considering as unique the redundant ones. It 
should be pointed, that both unipartite projections (HDGN or ODGN) are based on 
genes that are associated with at least one same disease in OMIM and Orphanet, 
respectively. The resulting network, in turn, was compared with the dataset of pairs of 
genes obtained after to compute similarity scores between genes. It resulted in a cross-
tabulation of overlapped and non-overlapped gene pairs to be considered respectively as 
true positives and false positives (Table 1). 
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Table 1. Binary classification based on the intersection of gene pairs 
 Genes Gene pairs 
Pathophenotypic similarities 1812 1309578 
Unipartite projections (HDGN + ODGN) 1760 8372 
Overlapped or True Positives (TP) 1064 3271 
Non-overlapped or False Positives (FP) 748 1306307 
 
This classification model has been used to predict the optimal threshold of 
pathophenotypic similarity score involving a pair of genes on the same pathological 
process (Figure 4).  
 
Figure 4. ROC curve and optimal threshold of pathophenotypic similarity. In this 
performance analysis, those pairs of genes showing pathophenotpic similarity and co-associated with at 
least one diseases are considered as true positives and the rest of gene pairs showing pathophenotypic 
similarity are considered as false positive. Black circle indicates the coordinates (0.07 and 0.8 for false 
and true positive rates, respectively) for the Youden's index (1.39) that determines the optimal threshold. 
The color palette maps for each threshold the corresponding similarity scores. ROCR  [7] and pROC [8] 
packages were used to represent and calculate optimal threshold. 
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As can be appreciated from the ROC curve the pathophenotypic similarity (similarity 
score) is a good indicator to assess the underlying relationships of genes in a particular 
pathological process. The optimal threshold of similarity score that maximizes the 
trade-off between the rates of true and false positives is 1.39 (which corresponds to the 
92th percentile, Table 2) for the Youden's index [9,10] (Figure 4). We also calculated 
the inflection point at the curvature in Figure 3, which can be worth as an alternative 
approach to locate the turning point. We fit the curve of computed similarity scores to 
an exponential function and the inflection point results in 1.55 corresponding to the 95th 
percentile (Table 2). This curve-fitting analysis was carried out in MATLAB. 
 
Table 2. Results using top score percentiles as cutoffs 
Percentile Score Genes Gene pairs 
92th 1.39a 1759 99777 
95th 1.55b 1742 60742 
98th 1.82 1705 26197 
99th 2.04 1601 13098 
a Patho-phenotypically meaningful threshold by ROC curve analysis. 
b Turning point fitting similarity scores to an exponential function. 
 
Therefore, we have two different thresholds to estimate the appropriate cutoff to be used 
to build the pathophenotypic similarity gene network. However, the 92th and 95th 
percentiles are located in regions under the influence of large clusters of non-specific 
similarities. For instance, we observe that similarities with scores below 1.5 show 
abrupt changes in the number of genes (as can be seen in Figure 2). Thus, we carried out 
a more detailed analysis for these regions by filtering all similarity scores below 1.39, 
which could be considered as the patho-phenotypically meaningful threshold (Figure 4).  
In particular, the number of genes begins to drop around the value of 20.000 computed 
similarities scores (Figure 5). In this case, the score in the 98th percentile (1.8179) 
represents a reference value from which to ensure high specificity for pathophenotypic 
similarities without losing information. Therefore, 1.8179 corresponds to the lowest 
similarity value at the top 2% of all ranked scores and the most appropriate cutoff to 
build PSGN, for the reasons discussed above. 
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 Figure 5. The number of genes and gene pairs for each similarity score cutoffs. One 
thousand equidistant cutoffs were established along the range of similarity scores from the 92th percentile, 
it means removing scores below 1.39. All gene pairs with a score equal or greater than the cutoff were 
selected and resulting genes were counted. Red circles and vertical lines indicate exact location for 95th, 
98th and 99th percentiles. 
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Table S8. Spearman correlations between gene degrees in PSGN and HDGN/ODGN 
 HDGN ODGN 
Class n (genes) rs  P-value n (genes) rs  P-value 
MD-MGa - - - - - - 
MD-PG 247 0.06 3.4E-01 280 0.11 6.6E-02 
PD-MG 226 0.26 7.3E-05 446 0.25 7.4E-08 
PD-PGb 303 0.06 3.2E-01 485 0.13 4.2E-03 
All genesc  528 0.17 9.2E-05 931 0.22 1.0E-11 
a Biunivocal genes are not present in diseases causing gene networks. 
b Pleiotropic genes associated with at least one polygenic diseases. 
c  All intersected genes between PSGN and HDGN or ODGN respectively. 
 
Page 114 of 210
Ta
bl
e 
S9
. S
pe
ar
m
an
 c
or
re
la
tio
n 
be
tw
ee
n 
ge
ne
 d
eg
re
es
 in
 P
SG
N
 a
nd
 b
io
m
ol
ec
ul
ar
 in
te
ra
ct
om
es
 
 
PI
N
  
M
G
N
 
FG
N
 
N
et
w
or
k 
C
la
ss
 
n 
(g
en
es
) 
r s
  
P-
va
lu
e 
n 
(g
en
es
) 
r s
  
P-
va
lu
e 
n 
(g
en
es
) 
r s
  
P-
va
lu
e 
H
D
N
 
M
D
-M
G
 
55
5 
0.
13
 
2.
9E
-0
3 
87
 
-0
.0
1 
9.
4E
-0
1 
63
4 
 0
.0
1 
7.
7E
-0
1 
H
D
N
 
M
D
-P
G
 
42
0 
0.
18
 
2.
6E
-0
4 
31
 
-0
.0
2 
9.
3E
-0
1 
45
6 
-0
.0
4 
4.
0E
-0
1 
H
D
N
 
P
D
-M
G
 
15
8 
0.
06
 
4.
5E
-0
1 
29
 
 0
.3
7 
5.
0E
-0
2 
17
5 
-0
.0
6 
4.
3E
-0
1 
H
D
N
 
P
D
-P
G
b  
24
7 
0.
10
 
1.
0E
-0
1 
14
 
-0
.2
5 
3.
9E
-0
1 
26
7 
-0
.1
2 
6.
0E
-0
2 
H
D
N
 
A
ll 
ge
ne
s 
in
 H
D
N
c  
11
75
 
0.
15
 
2.
0E
-0
7 
15
0 
 0
.1
0 
2.
4E
-0
1 
13
13
 
 0
.0
1 
6.
5E
-0
1 
O
D
N
 
M
D
-M
G
 
36
4 
0.
11
 
3.
0E
-0
2 
68
 
 0
.0
2 
8.
7E
-0
1 
41
1 
 0
.0
1 
9.
3E
-0
1 
O
D
N
 
M
D
-P
G
 
31
2 
0.
21
 
2.
2E
-0
4 
26
 
-0
.2
3 
2.
7E
-0
1 
34
0 
-0
.1
0 
6.
3E
-0
2 
O
D
N
 
P
D
-M
G
 
32
2 
0.
18
 
1.
3E
-0
3 
40
 
 0
.1
6 
3.
4E
-0
1 
35
4 
-0
.0
4 
4.
3E
-0
1 
O
D
N
 
P
D
-P
G
b  
38
4 
0.
13
 
1.
4E
-0
2 
28
 
 0
.0
1 
9.
5E
-0
1 
42
3 
-0
.0
1 
9.
3E
-0
1 
O
D
N
 
A
ll 
ge
ne
s 
in
 O
D
N
c  
11
51
 
0.
16
 
3.
2E
-0
8 
14
9 
 0
.0
7 
3.
9E
-0
1 
12
79
 
 0
.0
1 
5.
9E
-0
1 
a  N
et
w
or
k 
ba
se
d 
on
 fu
nc
tio
na
l s
im
ila
rit
ie
s 
fro
m
 b
io
lo
gi
ca
l p
ro
ce
ss
es
 b
ra
nc
h 
of
 G
en
e 
O
nt
ol
og
y.
 
b  P
le
io
tro
pi
c 
ge
ne
s 
as
so
ci
at
ed
 w
ith
 a
t l
ea
st
 o
ne
 p
ol
yg
en
ic
 d
is
ea
se
s.
 
c  A
ll 
in
te
rs
ec
te
d 
ge
ne
s 
be
tw
ee
n 
th
e 
re
sp
ec
tiv
e 
bi
om
ol
ec
ul
ar
 in
te
ra
ct
om
e 
an
d 
P
S
G
N
. 
 
Page 115 of 210
!CHAPTER 3. PUBLICATION 4  
 
 
 
 
 
 
PhenUMA: a Tool for Integrating the Biomedical 
Relationships among Genes and Diseases 
 
 
Rocío Rodríguez-López, Armando Reyes-Palomares, Francisca 
Sánchez Jiménez and Miguel Angel Medina 
 
 
BMC Genomics  
 
 
 
Print ISSN:  
Online ISSN: 1471-2164 
Supplementary Material:  Yes 
Status: Submitted 
DOI:  
Rights and Permissions:   
The copyright of this manuscript is reserved for authors until its definitive 
publication.  
Page 118 of 210
!CHAPTER 3. PUBLICATION 4  
 
 
 
 
 
 
 
 
Supplementary Material for: 
 
PhenUMA: a Tool for Integrating the Biomedical 
Relationships among Genes and Diseases 
 
Supplementary material INCLUDED in this Thesis: 
 
Additional file 1  
Evaluation of methods and integration of information.  Evaluation of the measures 
purposed by Resnik and the approach used by Robinson in the semantic similarity 
calculation and evaluation of the integration of phenotypic and functional relationships.  
 
Figure S1.  
ROC curves for functional and phenotypic relationships.  
 
Figure S2. 
Similarity and significance of the intersection between subsets and interactomes. 
 
Figure S3. 
Distribution of functional similarity scores in the subsets of inferred and phenotypically 
similar gene pairs.   
Page 135 of 210
!CHAPTER 3. PUBLICATION 5  
 
 
 
 
 
 
 
 
Network Medicine Approaches for Systematic 
Identification of Phenotype and Structural Variants 
Associations 
 
Armando Reyes-Palomares, et al.  
 
 
 
 
 
 
 
Print ISSN:  
Online ISSN:  
Supplementary Material:   
Status: Manuscript in preparation 
DOI:  
Rights and Permissions:   
The copyright of this manuscript is reserved for authors until its definitive 
publication.  
Page 147 of 210
! 
CHAPTER 4 
DISCUSSION 
Functional modularity in biological systems 
The modularity is an essential property to study the architecture of the 
functionality in biological systems, at whatever of their scale. This is one of the 
main arguments to evidence that genetic information is not the unique level of 
causality86, but there are many other biological scales determining the function. 
In this regard, systems biology approaches aim to take into account the 
dynamical singularities to understand how biological systems function4,5.  
 
 In the research group where this Thesis has been carried out, I have 
studied the modular and functional behaviour of the metabolism using a 
particular case of the sulfur amino acids. Our previous work modelling 
polyamine metabolism in mammals87 suggested an unexpected relevant role of S-
adenosyl methionine (SAM) in the control of polyamines levels. To evaluate it 
further, we decided that the first task within this Doctoral Thesis work would be 
the design of a metabolic model integrating those metabolic modules that are 
linked by SAM, such as the polyamine87 and methionine metabolism88. In 
addition, we also included the folate89,90 and glutathione metabolism91 for an 
extended view of the regulatory processes. Time-course simulations of our model 
suggest a relevant role of SAM in polyamines homeostasis. In proliferative 
conditions, MAT-II is expressed. This enzyme is inhibited by its own product 
(SAM); which cellular levels are decreased. SAM and ornithine are the 
immediate precursors of polyamines. Since polyamines are necessary for 
proliferation, their levels should be maintained or even increased under 
proliferative conditions.  Accordingly, we proposed alternative regulatory 
mechanisms in polyamine metabolism that depend on SAM availability. In silico 
experiments with our model under proliferative conditions indicate that the 
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diminished could be explained by an increased activity of ornithine 
decarboxylase (ODC). These predictions have been experimentally validated as 
can be deduced from the conclusions of the recent work published by Lu, Mato 
and co-workers92. This computational work illustrates how the metabolic 
modularity, in the case of amine metabolism, is an operative feature of the 
structure of the metabolic network. Additionally, this model is also useful to raise 
novel hypotheses that will require experimental validation to amplify the relative 
information about complex biological systems. 
 
Evaluating disease modularity 
All the current hypotheses agree that the origin of biological modularity and the 
subsequent performance require genetic variations19,22,23. In this case, the genetic 
level is the unique level of reference to track the underlying evolutionary 
mechanism18. In the present section, I discuss the different perspectives about the 
relationships between genotypic and phenotypic variability. Both are measurable 
features that can show a different degree of "resistance" (robustness) to the 
change26,29. In contrast, living beings (as complex adaptive systems) require 
plasticity to face the constant fluctuations that occur in nature. Therefore, they 
need to be constantly changing their features to ensure their survival or –even– to 
improve their fitness (evolvability). 
 
 The complexity of the genotype-phenotype relationships is 
multidimensional because of the presence of multiples genotypes associated with 
the same phenotype, as well as the existence of different phenotypic traits 
associated with the same phenotype. For this reason, the one gene-one enzyme 
hypothesis should be considered more as an exception than the rule in biology. In 
this line, there is a very interesting debate about the pleiotropy45,47,93, defined as 
the multiple traits that can be associated with a genotype or a gene. This debate 
discusses actively if there is a universal or restricted pleiotropy, what means that 
every genotype has an effect on all the possible measurable traits43 or there is a 
modular pleiotropy where the effects of a genotype are restricted to a reduced 
number of traits45. This debate implicates to dig into the biological meaningful 
role of genes (or genotypes) in fitness but also for the expression of their related 
characters. For this purpose, the objective is to search for novel measurements of 
pleiotropy to evaluate traits more directly related to the biological function of 
genes (or a genotype). These phenotypes would be likely the reflection of the 
molecular functions that gene products may carry out into cells. In this sense, the 
relevance of the functions carried out by genes is the more appropriate approach 
to assess their role the different modules they take part in. 
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 As mentioned in the Introduction, the phenome is considered one of the 
‘omes that may provide new insights into science. But I want to be even more 
explicit: the deep phenotyping should be referred to high-throughput screening of 
cellular and molecular phenotypes in multivariate cellular states to get better 
correlations between traits and genetic variations. For instance, Andreas Wagner 
showed in a recent publication the potential benefits to study direct molecular 
phenotypes, such as transcription binding affinity, together with DNA 
variability38. 
 
 As far as possible with the current biomedical information available, 
further studies are necessary to trace which cellular and molecular mechanisms 
are underlying pathological phenotypes are necessary. For this purpose, our first 
issue was to define diseases in suitable terms to approach them as far as possible 
to their molecular and biological context. For that, we built and analysed the 
human pathophenome gene network 94 and this network was compared to the previously 
published disease networks called HDN95 and ODN96. Unlike these previous 
disease networks, the pathophenome uses semantic similarities. This 
pathophenotypic similarity was calculated for pairs of genes using their 
phenotypic annotations in the "Human Phenotype Ontology" and, subsequently, 
comparing their phenotypic spaces. The resulting human pathophenome 
network contains 1706 genes (nodes) and 26192 significant pathophenotypic 
similarities (edges). This network reveals a strong re-arrangement of the 
pathological relationships among genes and, moreover, they are measurable by 
phenotypic similarities. Many novel pathophenotypic interactions between genes 
have been uncovered. Additionally, pathophenotypic similarities and metabolic 
interactions of genes associated with maple syrup urine disease (MSUD) have 
been used to merge into a coherent pathological module. Our results indicate 
that pathophenotypes might contribute to discover pre-clinical stages and to 
identify underlying co-dependencies among disease-causing genes that are useful 
to describe disease modularity. 
 
Standardization efforts 
An integrative framework for metabolic modelling 
 
We developed a user-friendly application, named as Systems Biology Metabolic 
Modelling Assistant (SBMM Assistant, http://www.sbmm.uma.es/) able to 
integrate kinetic and metabolic information of any organism. SBMM assistant, 
works on the bases of an ontology-based mediator developed to integrate data 
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characterized by the following features: It is an SBML-compatible and friendly 
tool able to guide to the novel or experienced user to capture, enrich, generate 
and visualize biological networks, to make basic queries on enzymatic kinetics 
and regulation, and to annotate this information following the MIRIAM 
specifications. 
 
 In this sense SBMM assistant is an example of such a specific application, 
having the aim to act as a complementary tool (assistant) for metabolic modelling 
analysis programs. Thus, it is not only able to capture, enrich and store 
information in models, but also helps the cross-talk among the different resources 
and tools in a friendly way.   
 
An integrative framework for biomedical information 
 
 Within this Doctoral Thesis, we present PhenUMA 
(http://www.phenuma.uma.es/), a framework for the integrative analysis of 
biomedical information that can help with the discovery of alternative 
pathological roles of genes, biological processes and phenotypes. PhenUMA 
knowledge base includes pairwise relationships that result from: (i) repositories of 
genetic association studies (OMIM and Orphanet), protein-protein interactions 
(STRING) and metabolic interactions; (ii) network inferences in known 
relationships; and (iii) semantic similarity measurements using biomedical 
ontologies (Gene Ontology and Human Phenotype Ontology) for functional and 
phenotypic similarity, respectively. The workflow begins by building "seed 
networks", which are used as backbones and extended with phenotypic and 
functional associations, and can be later analysed to look for phenotypic or 
functional enrichment. We also report a systematic method to set the optimal 
threshold of phenotypic similarity that is suitable to detect meaningful 
relationships using association indices (i.e. jaccard index or hypergeometric test) 
and performance validation94.  
 
 The main advantage of PhenUMA over other systems is to unify network, 
semantic similarity and enrichment analysis in the same platform. This will allow 
users to manage vast amount of a priori unconnected (or at least unreachable in 
an easy way) biomedical data. This framework is useful to evaluate phenotypic 
similarities between functionally related genes and clusters of genes or medical 
conditions sharing specific clinical features. Furthermore, PhenUMA aids the 
evaluation of the enrichment of phenotypes or biological attributes in reported 
results. Clusters of phenotypically related diseases are more coherent in 
PhenUMA compared to other similar resources.  
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 PhenUMA represents an advance towards the use of new technologies for 
genomics and personalized medicine.  In a near future update, we will include 
phenotype-genotype association data and more repositories of curated molecular 
interactions. Since PhenUMA is under continuous development, user comments 
and suggestions are welcome. 
 
Network medicine approaches using patient data 
The combined use of network analysis methods together genomic association 
studies for biomedical applications emerged as a new field, named as Network 
Medicine49,97. This is a promising approach, specially now, that the scientific 
community is assessing the main standards necessary for the expected increasing 
genome sequencing projects for the next years72,98. In this Thesis, I present a 
preliminary study comprising 4627 unbalanced CNVs in 3315 patients (cases) 
from a heterogeneous group of disorders showing developmental delay, 
intellectual disability and congenital malformations from DECIPHER 
Database78,99. Our aim has been to use individual clinical features to compare 
genotypic and phenotypic relationships among these patients. In particular, we 
present a combined analysis of network-based approaches with genetic 
association studies. To this end, we first have built a network where vertices 
symbolize patients and edges represent that both patients show both genotypic 
and phenotypic relationship. Subsequently, we use phenotypic enrichment 
analysis and clustering methods (using clique percolation method) to identify 
locus-phenotypic enrichment and novel phenotype-genotype associations, for this 
latter using a control data set of reference. This workflow allows us to identify 
more than 500 different genotype-phenotype associations. Finally, we use our 
results to build a high-resolution genomic map of phenotypes associations with 
overlapping CNVs between patients. This study illustrates how network medicine 
approaches are very helpful to characterize very low prevalent disorders as those 
included analysed in this case data set. The use of integrative analysis of large 
data sets provides clinicians and researchers both depth and wider interpretation 
of patient profiles. This works evidences the need to advance in consolidated 
standards and public repositories of genomic and health data for the 
advancement of genomic medicine. 
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CHAPTER 5 
CONCLUSIONS 
 
 
Conclusions from Objective 1 
An integrated model of the metabolism of polyamines and sulfur amino acids has 
been build from previously published mathematical models of its constituent 
modules. The model allows us to evaluate and predict the S-adenosyl methionine 
availability in different physiological conditions. The predictions of this model 
have been subsequently confirmed by independent experimental studies. 
 
Conclusions from Objective 2 
We have developed a workflow for integrating metabolic and kinetic data in a 
user-friendly tool to provide access to this information in a unique platform. This 
tool is helpful in the development of similar projects related to objective 1. 
 
Conclusions from Objective 3 
We have shown how semantic similarity based on pathological phenotypes is a 
useful resource to construct gene networks that allow us to discover the molecular 
mechanism underlying the development of genetic diseases. Phenotypic similarity 
enables to identify and evaluate the distinct components from the same metabolic 
module, as in the case of phenotypically similar genes to those associated with 
Maple Syrup Urine Disease. 
 
Conclusions from Objective 4 
We have built an integrative framework for biomedical and biological 
information that it is useful to study phenotypic and functional relationships 
between genes, as well as to cluster disease that shared similar phenotypes. 
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The combination of network-based analysis with genetic association studies 
improves the systematic identification of significant relationships between 
genomic regions associated with pathological phenotypes from a heterogeneous 
group of patients with low prevalence diseases. 
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CHAPTER 5 
CONCLUSIONES 
Conclusiones derivadas del objetivo 1 
Se ha construido un modelo integrado del metabolismo de las poliaminas y de los 
aminoácidos azufrados a partir de modelos matemáticos de sus módulos 
constituyentes previamente publicados. El modelo permite estudiar y predecir la 
disponibilidad de S-adenosil metionina ante distintas condiciones fisiológicas. Las 
predicciones de este modelo han sido posteriormente confirmadas en estudios 
experimentales independientes.  
 
Conclusiones derivadas del objetivo 2. 
Se ha desarrollado un "workflow" para integrar información metabólica y 
cinética en una herramienta de fácil manejo para que los usuarios puedan 
acceder a esa información desde una única plataforma. Esta herramienta ayuda 
al desarrollo de proyectos similares al relacionado con el objetivo 1. 
 
Conclusiones derivadas del objetivo 3 
Hemos mostrado cómo la similitud semántica basada en los fenotipos patológicos 
es un recurso útil para construir redes de genes que permitan descubrir los 
mecanismos moleculares implicados en el desarrollo de las enfermedades 
genéticas. La similitud fenotípica posibilita identificar y estudiar los distintos 
componentes de un mismo módulo metabólico, como es el caso de los genes 
fenotípicamente similares a los relacionados con la enfermedad del jarabe de 
arce. 
 
Conclusiones derivadas del objetivo 4 
Se ha construido un "framework" para integrar información biomédica y 
biológica que es útil para estudiar relaciones fenotípicas y funcionales entre 
genes, así como para agrupar enfermedades que comparten fenotipos similares. 
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La combinación del análisis de redes y estudios de asociación genética ha 
permitido identificar de forma sistemática relaciones significativas entre regiones 
genómicas asociadas a fenotipos específicos en un grupo heterogéneo de 
pacientes con enfermedades de baja prevalencia. 
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GLOBAL SUMMARY OF RESULTS 
METABOLIC MODELLING 
Cellular metabolism depends on enzymes and transporters that are differentially 
expressed in mammal cells. Most of these enzymes or transporters are poorly 
characterized, although it is well known that their dysfunctions are associated 
with inherited metabolic diseases. The metabolism is a complex biological system 
and requires systemic approaches, such as the dynamic analysis of biochemical 
reaction networks to understand how metabolic processes are regulated. Indeed, 
the kinetic modelling is among the reference computational techniques –together 
with the structural analysis of metabolic networks– in this resurgence of the 
systemic view of the biology. According to the notion of the metabolism as a 
hierarchical and modular structure, we evaluate how the metabolism conserves 
functionality by integrating discrete metabolic modules into a single model. 
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metabolic information from databases 
Advances in systems biology have boosted the development of computational 
tools and resource facilities for modelling the pre-existing biological knowledge 
from multiple perspectives. Through international cooperation and support of 
many research groups, there is a wide catalogue of tools amongst which I would 
like to highlight all those that are compatible with the Systems Biology Markup 
Language (SBML). Most of the software compatible with SBML is also accessible 
to users coming from different disciplines and who are not familiar with 
programming language. During the first phase of my pre-doctoral training I set 
up an innovative educational methodology by designing a practical session for 
metabolic modelling. 
 
 This practical session consists of two distinct parts, the management of 
metabolic data and the design of a simple metabolic model of the glycolysis. For 
the first part, we select many different resources, databases and software, to 
acquire metabolic data such as metabolic pathways (KEGG, Reactome or 
Panther), biochemical reaction kinetics data (BRENDA or Sabio-RK) and 
repositories of published models in SBML (JWS Online Cellular Systems 
Modelling and BioModels). In the second part, students design and simulate a 
simple model, using CellDesigner and CoPaSi, to illustrate how glycolysis 
regulation exhibits an oscillatory behaviour. We conclude that this practical 
session is very useful and allow students to understand how biochemical reactions 
take place into cells, by using time-course simulations to explore changes in 
metabolite concentrations and metabolic fluxes. 
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An integrated metabolic model of the metabolism of polyamines and 
sulfur amino acids in hepatocyte. 
S-Adenosyl methionine (SAM) is the main donor of methyl groups and a 
metabolic hub that interconnects the polyamine, histamine, sulfur-containing 
amino acid and folate metabolisms. Previous experimental studies have proposed 
SAM as a physiological biomarker of cell stage in hepatocytes, as well as a key 
regulatory metabolite. SAM levels decrease after a switch in the genetic 
expression of two methionine adenosyltransferase (MAT) genes, from MAT1A to 
MAT2A. This switch is induced under proliferating conditions in hepatic cells 
(i.e. hepatocellular carcinoma). Our previous work in the modelling of the 
polyamine metabolism in mammals suggested an unexpected relevant role of 
SAM in the control of polyamines levels. Previous computational works suggested 
the role of polyamines in this change of activity by distinct MATs. Here we 
studied how decreased levels of SAM, the main biosynthetic precursor of 
polyamines, affect polyamine metabolism. We also propose a mathematical 
model to explain which mechanisms are involved to restore –or even to increase– 
spermine and spermidine levels under proliferative conditions. 
 
 For this purpose, we designed a metabolic model integrating those 
metabolic modules that are linked by SAM, such as polyamine and methionine 
metabolism. In addition, we also included the folate and glutathione metabolism 
for an extended view of the regulatory processes. The methodological approach 
consisted in to analysis of a mathematical model of ordinary differential equations 
(ODEs). First, we analysed individually those models previously published and 
they were contrasted to the experimental results. Later, we combined these 
models in a single model, in a SBML file, and we created a second version of the 
model considering the proliferative conditions. Previous models and the two 
combined versions of the models were submitted to BioModels Database 
(BIOMD0000000450 and MODEL1305060000). 
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polyamines homeostasis. In proliferative conditions, MAT-II is expressed which 
is inhibited by its own product, S-adenosylmethione. Therefore, cellular levels of 
SAM are decreased. SAM and ornithine are the main precursors of polyamines. 
Since polyamines are necessary for proliferation, their levels should be 
maintained or even increased.  Accordingly, we proposed alternative regulatory 
mechanisms in the polyamine metabolism that depends on SAM availability. In 
silico experiments with our model under proliferative conditions, indicate that the 
metabolic flux redistribution to balance polyamines levels by lowered levels of 
SAM could be explained by an increased activity of ornithine decarboxylase 
(ODC). These predictions can be considered as experimentally validated as can 
be deduced from the conclusions of the recent work published by Mato and co-
workers. 
 
 This computational work illustrates how the metabolic modularity, in the 
case of amine metabolism, is an operative feature of the structure of metabolic 
networks. Additionally, this model is also useful to raise novel hypothesis that will 
require experimental validation to amplify the relative information about 
complex biological systems. 
 
 
An ontology-based tool to integrate metabolic data for kinetic 
modelling 
Metabolic modelling requires data about biochemical reactions, enzymes, 
metabolites and modulators (activators or inhibitors), as well as to recognize those 
classical functional modules know as metabolic pathways. One of the most 
recognised problems in the field of kinetic modelling is the lack of kinetic data 
about the activity of enzymes. 
 
 We developed a user-friendly application, named as Systems Biology 
Metabolic Modelling Assistant (SBMM Assistant, http://www.sbmm.uma.es/) 
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assistant, works on the bases of an ontology-based mediator developed to 
integrate data from KEGG, CHEBI, BRENDA and SABIORK. SBMM 
assistant is characterized by the following features: It is an SBML-compatible and 
friendly tool able to guide to the novel or experienced user to capture, enrich, 
generate and visualize biological networks, to make basic queries on enzymatic 
kinetics and regulation, and to annotate this information following the MIRIAM 
specifications. Semantic-web technologies have been claimed to be applied 
specifically to solve the present shortcomings in the workflow of metabolic 
modelling, in this sense SBMM assistant is an example of such a specific 
application, having the aim to act as a complementary tool (assistant) for 
metabolic modelling analysis programs. Thus, it is not only able to capture, 
enrich and store information in models, but also helps the cross-talk among the 
different resources and tools in a friendly way.   
 
 This resource has been used to enrich of data other databases about 
peroxisomal disorders (PeroxisomeDB 2.0) and to generate a pilot knowledge 
base (Amine Knowledge Base: asp.uma.es/amineKB). A subsequent version of 
SBMM assistant, names as SBMM Assistant: Social Pathway Annotation, was 
oriented to the automatic curating process of databases. These efforts are, 
specially, interesting in the case of inborn errors of the metabolism to share 
information due to limited biomedical information about these rare genetic 
diseases. 
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NETWORK MEDICINE APPROACHES 
A systemic view of rare diseases, perhaps not so rare 
Systems biology has been proposed in numerous studies to increase 
understanding of complex diseases like cancer or neurodegenerative diseases. 
Complex diseases are usually polygenic and each genetic variant point to a risk 
value, but they also show and strong multifactorial and environmental influences. 
On the other hand, rare diseases use to be genetically characterized and there is 
variability in terms of the number of genes that may be associated with disease. 
In addition, their low prevalence (less than 0.05% in the population) and their 
typically conserved clinical features make them very interesting from a biological 
point of view. Our hypothesis is that the incidence of these diseases in the 
population is the consequence of certain biological constraints and susceptible to 
be studied by a systemic view. 
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Network biology: a direct approach to study rare diseases genetic 
relationships 
A dataset of 2125 RDs associated with 2331 genes has been modelled and 
analysed by network biology methods. These analyses were carried out attending 
to the relationships patterns between genes and RDs, for this reason we subset 
genes according to the number of genes associated with diseases (evaluating 
pathological gene co-associations) and the number of diseases associated with a 
gene (pleiotropy). Functional characteristics and topological properties of rare 
disease-causing genes have been analysed in metabolic and protein-protein 
interactions (PPI) networks from published interactomes. We have used different 
tools like BioMart, ClueGO, and Cytoscape plugins to analyse this dataset with 
relevant biological knowledge. Different R packages and own scripts were used 
for data management and statistical analysis. 
 
 Our results indicate that the associations between genes and rare diseases 
depend on complex interactions, but we observe shared and distinguishable 
features in each subset of genes. Genes associated with monogenic rare disease 
are functionally different from those genes that are associated with more than one 
RDs.  RDs related genes exhibit a functional bias according to the biological 
network in which they are mainly implicated, either metabolic or protein-protein 
interactions networks. In particular, there is likely a dependence on the functional 
context in which genetic variants cause dysfunctions. Therefore, network analyses 
are useful to get a deeper understanding about the molecular aetiology and 
intervention capacity on low-prevalence diseases.  
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Diseases Networks are useful to study the molecular complexity of genetic 
diseases. Two main disease networks, "the human diseases networks" (HDN, Goh 
et al. 2007) and "the orphan disease networks" (ODN, Zhang et al. 2007), have 
been published to date among others. However, in these networks, each single 
node is a disease, characterized as a set of clinical features descriptions 
(pathophenotypes) represented as pathological entities. Most of these diseases 
were described using evidence-based medicine methods allowing physicians 
systematically to differentiate types and sub-types of diseases. Therefore, the 
representation of diseases as entities, without relationships to other phenotypically 
similar diseases, affects to network medicine methods. We hypothesize that the 
pathophenotypic relationships among diseases can help to find out interrelations 
in molecular events originated by mutations. 
 
 In this work, we built and analysed the human pathophenome network to 
be compared to HDN and ODN. Unlike these previous networks, the 
pathophenome uses semantic similarities. The pathophenotypic similarities were 
calculated between pair of genes annotating phenotypic abnormalities in the 
"Human Phenotype Ontology" and, subsequently, comparing gene phenotypic 
spaces. The resulting human pathophenome network contains 1706 genes (nodes) 
and 26192 significant pathophenotypic similarities (edges). This network reveals a 
strong re-arrangement of the pathological relationships among genes and, 
moreover, they are measurable by phenotypic similarities. Many novel 
pathophenotypic interactions between genes have been uncovered. Our results 
indicate that pathophenotypes might contribute to discover pre-clinical stages 
and co-dependencies among disease- causing genes. 
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PhenUMA: an integrative tool of biomedical relationships among 
genes and diseases. 
Several types of regulatory genetic interactions can be directly or indirectly 
associated with human mutations. These gene-gene relationships are usually 
based on their co-associations to biological processes, co-existence in cellular 
locations, co-expression in cell lines, physical interactions, etc. In addition, 
pathological processes can share similar phenotypic features and mutations in the 
same genomic location, or even to exhibit genetic variations in different genomic 
regions. Thus, integrative analyses of all these complex interactions can help us 
prioritize those relationships between genes and diseases most deserving to be 
studied by researchers and physicians. 
 
 PhenUMA (www.phenuma.uma.es) is a web application to build, analyse 
and visualize networks based on both functional and phenotypic relationships. 
This novel tool uses semantic similarity methods to study interconnected genes 
using their functional and phenotypic features. Furthermore, phenotypic 
similarities can be useful to analyse clusters of diseases sharing specific 
phenotypes or to find diseases related to reported phenotypes. This tool enables 
the inference of new links relative to genes, biological functions and diseases. 
Conclusions: This framework provides networks built using integrated 
information from biomedical and biomolecular data repositories. PhenUMA 
represents a further step towards the advance of new technologies for genomic 
and personalized medicine. 
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networks 
Phenotypic variance is a feature of all biological systems under the influence of 
complex molecular process and environmental changes. Network medicine is a 
promising field based on systems biology approaches to study biomedical issues 
through networks. These network models provide an integrative framework for 
the analysis 'omics data to characterize the molecular aetiology of pathological 
processes. Previous network models considered diseases as conceptual entities. 
Here, we use patients as the nodes in combination with their genetic information. 
In this work, we will explore the benefits of using individual phenotypic profile of 
patients to explorer their similarities. Here we also present a systematic method 
to study patients sharing phenotypes and presenting similar copy number 
variations, structural variants. Finally, we report a high-resolution map of 
pathogenic phenotypes associated with their respective significant genomic 
locations.  
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RESUMEN GLOBAL DE LOS RESULTADOS 
A lo largo de los trabajos de investigación desarrollados recogidos en esta tesis he 
participado en más de 20 congresos nacionales e internacionales. Por imperativo 
legal, se exige a los doctorandos que presenten un resumen de más de 5000 
palabras que se ajusta muy poco a lo que desde mi punto de vista es un resumen. 
A pesar de que la medida a priori no me pareció adecuada a la estructura que yo 
he decidido para mi Tesis Doctoral por compendio de artículos, he 
reconsiderado junto con mi directores que una forma interesante para rastrear y 
hacer un seguimiento de la evolución de mi trabajo es precisamente ver lo que he 
presentado en cada uno de estos congresos, hasta la fecha. 
 
MODELADO METABÓLICO. 
El metabolismo celular depende de enzimas y transportadores que se expresan de 
forma diferencial en las células de mamíferos. La gran mayoría de enzimas o 
transportadores están pobremente caracterizados, pero sí se sabe que sus 
disfunciones son el origen de muchas enfermedades, enfermedades metabólicas 
hereditarias. El metabolismo es un sistema biológico complejo que requiere de 
abordajes sistémicos, tales cómo el análisis dinámico de redes de reacciones 
bioquímicas para entender como se regulan los procesos metabólicos. De hecho, 
el modelado cinético está entre las técnicas computacionales de referencia –junto 
con el análisis estructural de redes metabólicas– en este resurgimiento del 
enfoque sistémico de la biología.  
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una estructura jerárquica y modular, nosotros estudiamos cómo el metabolismo 
conserva su funcionalidad integrando módulos metabólicos discretos en un 
mismo modelo. 
 
Introducción al modelado metabólico y a la gestión de información 
metabólica en bases de datos 
Los avances en la biología de sistemas, han propulsado el desarrollo de 
herramientas y servicios de recursos computacionales para modelar el 
conocimiento biológico preexistente desde múltiples perspectivas. Gracias a la 
cooperación y a la competitividad entre grupos se han desarrollado un amplio 
catálogo de herramientas, entre las que me gustaría destacar aquellas orientadas 
al análisis de reacciones bioquímicas y que son compatibles con el formato SBML 
(Systems Biology Markup Language). Muchos de estos programas suelen ser accesibles 
a un público interdisciplinar que no está familiarizado al uso de lenguajes de 
programación. En la experiencia de poner en marcha algunas de estas 
herramientas encontramos -entre muchas otras aplicaciones- una interesante y 
sencilla metodología docente. Durante la primera fase de mi formación pre-
doctoral diseñé una sesión práctica seleccionando recursos bioinformáticos, como 
programas y bases de datos, para la modelización de rutas metabólicas. La 
primera parte de la sesión práctica se centró en capturar información puntual de 
bases de datos de rutas metabólicas (REACTOME y Panther), de carácter 
enzimológico (BRENDA) y otras de modelos publicados en SBML (JWS Online 
Cellular Systems Modelling y BioModels). La segunda parte de la sesión, 
consistió en desarrollar un sencillo modelo para estudiar de forma ilustrativa la 
dinámica oscilatoria de la glucólisis usando programas como CellDesigner y 
COPASI. Podemos concluir que con esta práctica los alumnos no solo se han 
introducido en la gestión de información metabólica de origen experimental en 
distintas bases de datos, sino que mediante la monitorización de un tutorial han 
realizado simulaciones y el análisis del estado estacionario de un modelo 
oscilatorio de la glucólisis. 
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Integración modular y funcional del metabolismo.  
Un modelo integrado del metabolismo de poliaminas y aminoácidos 
azufrados en hepatocitos. 
La S-adenosilmetionina (SAM) es el principal donador de grupos metilo y un 
"hub" metabólico que interconecta el metabolismo de poliaminas, histamina, 
aminoácidos azufrados y folatos. Estudios previos proponen que SAM es un 
marcador fisiológico del hepatocito y un elemento clave de regulación 
metabólica. Los niveles de SAM disminuyen cuando se produce un cambio de 
expresión génica entre las distintas metionina adenosiltransferasas (MAT) de 
MAT-I/III a MAT-II, en condiciones de proliferación celular (como es el caso de 
los hepatocarcinomas). Nuestro trabajo previo en el modelado del metabolismo 
de poliaminas en mamíferos sugiere un papel más relevante de SAM en el 
metabolismo de poliaminas que el hasta entonces reconocido. Algunos trabajos 
biocomputacionales han estudiado el papel de la activación de las poliaminas 
ante el cambio de actividad por las distintas MATs. Sin embargo, este estudio 
previo ha considerado poco significativo el flujo de SAM como precursor de 
espermina y espermidina. Nuestro objetivo era demostrar que en condiciones de 
proliferación celular, en las que los niveles de SAM disminuyen, aumentan las 
tasas de biosíntesis de poliaminas para mantener el pool de las mismas.  
 
 Para ello se diseñó un modelo metabólico que integra aquellos módulos 
metabólicos que interconecta SAM, tales como el metabolismo de las poliaminas, 
los ciclos de los folatos y de los metilos activados. El enfoque metodológico ha 
consistido en desarrollar un modelo matemático en un sistema de ecuaciones 
diferenciales ordinarias. En un primer lugar, se analizaron de forma individual 
los modelos previamente publicados y se contrastaron con datos experimentales. 
Posteriormente, se realizó la integración de toda la información en ficheros 
SBML generado dos versiones distintas del modelo, una para condiciones 
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BioModels (BIOMD0000000450 and MODEL1305060000). 
 
 Las simulaciones de nuestro modelo sugieren un papel importante de 
SAM y acetil-CoA en la homeostasis de poliaminas, algo que no se había 
considerado en estudios experimentales previos. En estado proliferativo actúa 
MAT-II que es inhibida por su propio producto, SAM,  bajando sus niveles 
celulares. SAM junto con la ornitina son los precursores inmediatos de 
poliaminas. En estado proliferativo las poliaminas son relevantes y sus niveles 
celulares se mantienen e incluso aumentan. En este sentido, se proponen 
mecanismos de regulación alternativos en el metabolismo de las poliaminas que 
dependan directamente de los niveles de SAM. Nuestro modelo integrado, 
propone que la redistribución de flujos metabólicos per se, compensa la perdida 
del precursor, SAM, fundamentalmente por el aumento de actividad de ODC. 
Nosotros observamos que, en función del estado fisiológico celular, las poliaminas 
pueden ser un importante destino metabólico de SAM. 
 
 Las conclusiones derivadas de este modelo se pueden considerar 
demostradas experimentalmente, tal y como se puede desprender de las 
conclusiones de los trabajos publicados por el grupo del Dr. Mato y 
colaboradores 92, un trabajo experimental que se publicó posteriormente a 
nuestro modelo. Este trabajo de la biología computacional ejemplifica cómo la 
modularidad metabólica en el contexto del metabolismo de aminas en mamíferos 
es completamente operativa. Además, este modelo ayuda a su vez a plantear 
nuevas hipótesis que precisan de validación experimental para amplificar la 
información relativa a los sistemas biológicos complejos. 
 
Una herramienta basada en ontologías para la integración de 
información metabólica para modelado cinético 
El modelado metabólico precisa de todo el conocimiento relacionado con las 
reacciones, las enzimas, los metabolitos, los modificadores (activadores e 
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el terreno del modelado cinético uno de los más reconocidos problemas es la 
laguna de conocimiento de la cinética de las enzimas. 
 
 En el terreno de la integración, hemos desarrollado una herramienta, 
denominada Systems Biology Metabolic Modeling Assistant (SBMM Assistant: 
www.sbmm.uma.es) capaz de integrar información cinética y metabólica sobre 
cualquier enzima de cualquier organismo. SBMM Assistant es una aplicación 
online compatible con SBML que sirve de guía al usuario para hacer consultas 
básicas de metabolismo, crear redes metabólicas, consultar parámetros cinéticos 
y anotar la información siguiendo las especificaciones de MIRIAM. Por el 
momento, dicha aplicación integra, mediante un sistema mediador basado en 
ontologías, una selección de la información metabólica disponible en KEGG, 
CHEBI, BRENDA y SABIORK. Esta información integrada permite generar un 
entorno rico en datos metabólicos del conjunto de reacciones bioquímicas 
involucradas en nuestro estudio. 
 
 Este recurso ya se está aplicando en el terreno de las enfermedades raras 
para estudiar algunas patologías relacionadas con el metabolismo de aminas y 
aminoácidos y para el desarrollo y enriquecimiento de una base de datos sobre 
proteínas peroxisomales (PeroxisomeDB). También se ha utilizado esta 
herramienta para desarrollar un piloto de generación facilitada de una base de 
datos (Amine Knowledge Base: asp.uma.es/amineKB) y una subsiguiente versión 
denominada "SBMM Assistant: Social Pathway Annotation" 
(http://www.sbmm.uma.es/spa/) que se diseñó para el curado automático de 
bases de datos. Estos esfuerzos son, especialmente, interesantes en el caso de las 
enfermedades raras para compartir información y debido a la escasez de datos 
biológicos. 
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APROXIMACIONES BASADAS EN REDES DE LA MEDICINA. 
La aproximaciones de la biología de sistema se están usando en numerosos 
estudios para comprender mejor las enfermedades complejas como el cáncer o 
las neurodegenerativas. Las enfermedades complejas suelen ser poligénicas y 
cada variante genética que esté asociada presenta a un valor de riesgo, pero ellas 
también muestran un fuerte influencia multifactorial y por el ambiente. Por otro 
lado, las enfermedades raras suelen estar claramente caracterizadas 
genéticamente y presentan una gran variabilidad en el número de genes 
involucrados. Además, su baja prevalencia (menos a un 0.05 % de la población) y 
el cuadro fenotípico típicamente conservado, las hace muy interesantes desde un 
punto de vista biológico.  
 
 Nuestra hipótesis es que la incidencia de esas enfermedades en la 
población es la consecuencia de determinadas restricciones biológicas que son 
susceptibles de estudiarse bajo una perspectiva sistémica. 
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relaciones genética entre enfermedades raras. 
Un conjunto de datos de 2150 enfermedades raras (ERs) y 2331 genes causantes 
de enfermedad se han usado para modelar y analizar utilizando métodos de la 
biología de redes. Estos análisis se han realizado teniendo en cuenta los patrones 
de relaciones que se producen entre esos genes y las ERs. Por eso hemos 
agrupado los genes en función del número de genes asociados a las enfermedades 
(genes que presentan una elevada co-asociación patológica) y el número de 
enfermedades asociadas al gen (pleiotropía). Las características topológicas y 
funcionales de los genes causantes de enfermedades raras fueron analizadas para 
una red metabólica y otra de interacciones proteína-proteína (PPI), interactomas 
publicados. Para ello he utilizado distintas herramientas tales como BioMart, 
ClueGO y plugins de Cytoscape para analizar este dataset con información 
biológica relevante. También he utilizado diversas librerías de R y mis propios 
scripts para la gestión, representación y el análisis estadístico de los datos. 
 
 Nuestros resultados indican que las asociaciones entre genes y 
enfermedades raras dependen de complejas interacciones, pero nosotros 
observamos características compartidas y diferenciables entre los distintos sets de 
genes. Por ejemplo, los genes asociados a una sola enfermedad rara monogénica 
son funcionalmente diferentes a aquellos genes que están asociados a más de una 
enfermedad. Los genes asociados a dichas enfermedades muestran un sesgo 
funcional según la red biomolecular metabólica o de interacciones entre 
proteínas a la que estén principalmente asociados. En concreto, en muchos casos 
hay una especie de dependencia entre las relaciones de genes causantes de 
enfermedades parecidas al contexto funcional en el que las variantes genéticas 
causan disfunciones. Por lo tanto, los análisis basados en redes son muy útiles 
para tener una comprensión más profunda de la etiología molecular así como de 
las posibilidades de intervención en las enfermedades de baja prevalencia. 
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!La red de genes que causan fenotipos patológicos 
Las redes de enfermedades son útiles para estudiar la complejidad de las 
enfermedades genéticas. Dos "diseasomas" o "enfermedomas" se han construido 
a partir de la información de las bases de datos más importantes de estudios de 
asociación genética, "the human diseases networks" generada a partir de los datos 
contenidos en OMIM (HDN, Goh et al. 2007) y "the orphan disease networks" 
generada a partir de los datos contenidos en Orphanet (ODN, Zhang et al. 
2011). En estas redes, cada nodo representa una enfermedad caracterizada por 
un conjunto de características clínicas y síntomas (fenotipos patológicos) que se 
consideran como conceptos unitarios. La mayoría de esas enfermedades se han 
descrito siguiendo los métodos de la medicina basada en la evidencia lo que ha 
permitido a los médicos diferenciar de forma sistemática entre tipos y subtipos de 
enfermedades para el diagnóstico. Pero la representación de las enfermedades 
como entidades, sin establecer las relaciones fenotípicas que presenta con otras 
enfermedades similares, afecta a las aproximaciones de la medicina en red. 
Nosotros postulamos que las relaciones basadas en los fenotipos patológicos entre 
las enfermedades pueden encontrar interrelaciones en los eventos moleculares 
que se desencadenan a partir de las variaciones genéticas. 
 
 En este trabajo, nosotros hemos construido y analizado una red del pato-
fenoma humano y lo hemos comparado con los "diseasomas" ya conocidos HDN 
y ODN. A diferencia de estas redes previas, el pato-fenoma utiliza similitud 
semántica. Estas similitudes pato-fenotípicas se calcularon entre pares de genes a 
partir de los pato-fenotípicos a los que se asocian en la "Human Phenotype 
Ontology" y, posteriormente, se compararon sus espacios pato-fenotípicos. La 
red del pato-fenoma humano resultante contiene 1706 genes (nodos) y 26192 
similitudes pato-fenotípicas entre pares de genes significativas (aristas). Esta red 
revela un fuerte re-ordenamiento de las relaciones pato-fenotípicas entre los 
genes y, más aún, se pueden medir a partir de su valor de similitud. Además, se 
han descubierto muchas nuevas relaciones pato-fenotípicas entre los genes. Estos 
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!resultados indican que los pato-fenotipos pueden contribuir a descubrir fases pre-
clínicas y co-dependencias entre los genes causantes de enfermedad. 
 
PhenUMA: una herramienta para integrar relaciones biomédicas entre 
los genes y las enfermedades 
Muchos tipos de interacciones genéticas reguladores puede estar directa o 
indirectamente asociadas al efecto de las mutaciones humanas. Esas relaciones 
gen-gen se basan usualmente en su co-asociación a procesos biológicos, su co-
existencia en localizaciones celulares, su co-expresión en líneas celulares, 
interacciones físicas entre proteínas, etc. Además, los procesos patológicos 
pueden compartir características fenotípicas similares y mutaciones en la misma 
localización genómica, o incluso mostrar variaciones genéticas en regiones 
genómicas diferentes. Por eso, análisis integrales que consideren todas esas 
relaciones complejas puede ayudarnos a priorizar aquellas relaciones entre genes 
y enfermedades que requieren ser estudiadas por investigadores y médicos. 
 
 PhenUMA (http://www.phenuma.uma.es/) es una aplicación web para 
construir, analizar y visualizar redes basadas en relaciones funcionales y 
fenotípicas. Esta nueva herramienta utiliza diversas medidas de similitud 
semántica para estudiar genes interconectados a partir de sus anotaciones 
funcionales y fenotípicas. Más aún, las similitudes fenotípicas se pueden utilizar 
para generar clústeres de enfermedades que comparten fenotipos específicos o 
encontrar enfermedades que estén asociadas a un conjunto de fenotipos. Esta 
herramienta permite la inferencia de nuevas relaciones en procesos patológicos 
de genes, procesos biológicos y enfermedades. Este marco de trabajo provee 
redes construidas a partir de información integrada de distintos repositorios de 
información biológica y biomédica. PhenUMA representa un paso más hacia el 
avance de las nuevas tecnologías para la medicina genómica y personalizada. 
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!Aproximaciones de la medicina de redes para estudiar las redes 
basadas en similitud fenotípica 
La variabilidad fenotípica es una característica de los sistemas biológicos bajo la 
influencia de procesos moleculares complejos y cambios ambientales. La 
medicina de red usa los modelos de redes para proveer un marco de trabajo 
integral para el análisis de esas complejas interacciones junto con datos 
procedentes de las técnicas ómicas. Estos datos permiten estudiar la etiología 
molecular y los procesos patológicos. La mayoría de esos modelos consideran a 
las enfermedades como entidades conceptuales y esta noción puede reducir de 
forma drástica la utilidad de los análisis basados en redes. En este trabajo, he 
explorado los beneficios de utilizar la los fenotipos para construir redes de 
enfermedades y de genes en base sus similitudes fenotípicas. Además, también 
presentamos un método sistemático para analizar los perfiles fenotípicos de 
pacientes que presentan mutaciones estructurales, variaciones de número de 
copias, potencialmente patogénicas. Finalmente, nosotros hemos aportado un 
mapa de alta resolución de los fenotipos patológicos y su grado de asociación a 
regiones genómicas específicas. 
 
Page 200 of 210
